nct_id,id,intervention_type,name,description,DRUGID,DRUGNAME,DRUGTYPE,DISEASES,DRUGSTAT,TARGNAME,PCHEMCID,HIGHSTAT,HIGHDISE
NCT04730323,12911794,Drug,tocilizumab,"participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. predefined parameters of disease severity were assessed 12 to 24 hourly. injection paracetamol 1g was administered before infusion. the response of the participants after tocilizumab administration was recorded based on clinical parameters (oxygen requirement, fever, need for invasive positive pressure ventilation), biochemical parameters (d-dimers, c-reactive protein (crp), ferritin, lactate dehydrogenase (ldh) levels), chest x-ray findings, and repeated pcr test for covid-19. any side effects noted after administration of tocilizumab were recorded.~any side effects noted after administration of tcz/ corticosteroid were recorded.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04345601,12912810,Biological,mesenchymal stromal cells,patients will be given the cell product by intravenous injection (into the vein through an iv line). dose:1 x 10^8 mscs.,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04604704,12928416,Drug,naltrexone,naltrexone at 4.5 mg/day,DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04474457,12929102,Drug,favipiravir,turkish patient cohort diagnosed with covid-19 and previously initiated treatment with favipiravir.,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04411433,12929369,Drug,favipiravir,"dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total).~the treatment duration may be extended up to 14 days with the evaluation of principle investigator.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04411433,12929370,Drug,favipiravir,"drug: favipiravir (3600 mg + 1600 mg) dosage and method of administration: in a regimen of 2x1800 mg (oral) loading dose on day-1 followed by 1600 mg maintenance dose (2x800 mg, 2 times daily) on day-2 to day-5 (5 days in total).~the treatment duration may be extended up to 14 days with the evaluation of principle investigator.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04411433,12929373,Drug,hydroxychloroquine,"dosage and method of administration for patients with mild possible or confirmed covid-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (200 mg oral 2 times daily) on day-2 to day-5 (5 days in total).~dosage and method of administration for patients with uncomplicated possible or confirmed covid-19: in a regimen of 400 mg (200 mg oral 2 times daily) throughout 5 days (5 days in total).",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04388826,12929475,Drug,veru-111,"respiratory distress syndrome, adult",DRUG0306,veru-111,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 53379371,,
NCT04388683,12929476,Drug,nitric oxide,"subjects will receive ino using the ino pulse device at a dose of 125 mcg/kg ibw/hr (equivalent to approximately 20 ppm). the clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). study drug will begin within 1 hour of randomization. beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6am, 2pm, and 10pm.",DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04372589,12929527,Drug,heparin,"low molecular weight heparin (lmwh) preferred therapeutic anticoagulant is enoxaparin. generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. alternatively, other subcutaneous lmwh used, including tinzaparin (175 anti-xa iu/kg subcutaneous once daily) or dalteparin (200 iu/kg subcutaneous once daily or 100 iu/kg subcutaneous twice a day).~unfractionated heparin (ufh) commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). intravenous infusion of ufh is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aptt) of 1.5-2.5x the reference value. if ufh is used, the availability of a local hospital policy that has specifies an aptt target in this range or an anti-xa value is a requirement.",DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04363346,12929557,Drug,ft516,"ft516 is an off-the-shelf cryopreserved nk cell product derived from an ipsc that was transduced with a high affinity, adam17 non-cleavable cd16 (fc receptor) that maintains cd16 on the cell surface, which remains fully functional after nk cell activation.",DRUG0053,ft516,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04351724,12929600,Drug,hydroxychloroquine,"hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or chloroquine 250mg 2-0-2, as available",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04351724,12929607,Drug,remdesivir,"200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04351724,12929607,Drug,remdesivir,"200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04351724,12929607,Drug,remdesivir,"200mg on day 1, thereafter 100mg for a total of 5-10 treatment days, according to local standards",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04346199,12929621,Drug,acalabrutinib,acalabrutinib- administered orally,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN,CID: 71226662,Approved,Leukemia
NCT04341584,12929633,Drug,anakinra,"treatment includes the administration of two iv infusions / day of anakinra kineret® 200mg (total 400 mg) at day 1 (d1), d2 and d3, two iv infusions / day of anakinra kineret® 100mg (total 200 mg) at day 4 (d4), and one iv infusion of anakinra kineret® 100mg (total 100 mg) at day 5 (d5).~in case of absence of improvement at d4 (absence of clinical improvement and absence of decrease of crp level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at d4, d5, d6 followed by a decrease at 200 mg/day at d7 and 100 mg/day at d8 and stop thereafter",DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04476706,12937057,Drug,clazakizumab,canakinumab,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04445272,12937171,Drug,tocilizumab,treatment with tocilizumab,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04369469,12937417,Biological,tocilizumab,"weight-based doses of ravulizumab will be administered intravenously on days 1, 5, 10, and 15.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04315948,12937550,Drug,remdesivir,"the lyophilized formulation of remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of remdesivir to be reconstituted with 19 ml of sterile water for injection and diluted into iv infusion fluids prior to iv infusion. following reconstitution, each vial contains a 5 mg/ml remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 ml (100 mg of remdesivir). it is supplied as a sterile product in a single-use, 30 ml, type 1 clear glass vial.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04315948,12937550,Drug,remdesivir,"the lyophilized formulation of remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of remdesivir to be reconstituted with 19 ml of sterile water for injection and diluted into iv infusion fluids prior to iv infusion. following reconstitution, each vial contains a 5 mg/ml remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 ml (100 mg of remdesivir). it is supplied as a sterile product in a single-use, 30 ml, type 1 clear glass vial.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04315948,12937550,Drug,remdesivir,"the lyophilized formulation of remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of remdesivir to be reconstituted with 19 ml of sterile water for injection and diluted into iv infusion fluids prior to iv infusion. following reconstitution, each vial contains a 5 mg/ml remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 ml (100 mg of remdesivir). it is supplied as a sterile product in a single-use, 30 ml, type 1 clear glass vial.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04315948,12937552,Drug,interferon beta-1a,"ifn-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. it will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 ml. the liquid should be clear to slightly yellow. do not use if the liquid is cloudy, discolored or contains particles. use a different syringe.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04315948,12937553,Drug,hydroxychloroquine,"hydroxychloroquine is supplied as film-coated 200 mg tablets. hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04703036,12942332,Dietary Supplement,n-acetylcysteine,this is a donor of the amino-acid cysteine (protein),DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04409262,12943074,Drug,remdesivir,participants will receive intravenous (iv) rdv,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04409262,12943074,Drug,remdesivir,participants will receive intravenous (iv) rdv,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04409262,12943074,Drug,remdesivir,participants will receive intravenous (iv) rdv,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04409262,12943075,Drug,tocilizumab,participants will receive iv tcz,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04663737,12946726,Drug,silmitasertib,capsules,DRUG0257,silmitasertib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN casein kinase II (CSK2)   CSK21_HUMAN; CSK22_HUMAN; CSK23_HUMAN; CSK2B_HUMAN,CID: 24748573,Phase 1/2,Cholangiocarcinoma
NCT04382625,12947378,Drug,hydroxychloroquine,"hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04723459,12982076,Other,ivermectin,mask with ivermectin nano solution,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04615429,12982815,Biological,mesenchymal stromal cells,administration of one single dose of allogenic mesenchymal stromal cells,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04492475,12983710,Drug,interferon beta-1a,"rebif (r) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. each 0.5 ml prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, usp; 27.3 mg mannitol, usp; 0.4 mg sodium acetate; and water for injection, usp.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04492475,12983712,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04492475,12983712,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04492475,12983712,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04486313,12983746,Drug,nitazoxanide,two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04482712,12983761,Drug,rapamycin,daily administration of a dose of investigational drug for up to 4 weeks while hospitalized,DRUG0167,rapamycin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN,CID: 6436030,Approved,Lymphangioleiomyomatosis
NCT04482712,12983761,Drug,rapamycin,daily administration of a dose of investigational drug for up to 4 weeks while hospitalized,DRUG0167,rapamycin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN,CID: 6436030,Approved,Lymphangioleiomyomatosis
NCT04359680,12984349,Drug,nitazoxanide,nitazoxanide 600 mg administered orally twice daily for six weeks,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04359095,12984358,Drug,colchicine,"generic drug distributed by the colombian health system as an insurance treatment for gout. it has been suggested that colchicine would be useful in sars covid 19 becouse its antiinflammatory effects through reduction of cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04348071,12984399,Drug,ruxolitinib,participants will receive 10 mg ruxolitinib twice daily.,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04343248,12984419,Drug,nitazoxanide,nitazoxanide 600 mg administered orally twice daily for six weeks,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04340232,12984435,Drug,baricitinib,subjects will receive a 2 mg oral dose of baricitinib.,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04335084,12984479,Drug,hydroxychloroquine,prophylaxis treatment for covid-19,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04668950,12992181,Drug,fluvoxamine,"up to 200mg per day (2 capsules per day) as tolerated, for approximately 15 days",DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04643678,12992292,Drug,anakinra,"patient will receive anakinra 100 mg sc injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus standard of care",DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04381936,12993259,Drug,hydroxychloroquine,hydroxychloroquine by mouth for a total of 10 days (see protocol for timing and dosage).,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04381936,12993260,Drug,azithromycin,azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04381936,12993262,Drug,tocilizumab,tocilizumab by intravenous infusion with the dose determined by body weight (see protocol for dosage),DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04381936,12993266,Drug,colchicine,"1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04381936,12993267,Drug,baricitinib,4 mg once daily by mouth or nasogastric tube for 10 days in total,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04381936,12993268,Drug,anakinra,for children ≥1 <18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). nb anakinra will be excluded from the randomisation of children <10 kg in weight.,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04372602,12993303,Drug,duvelisib,"-for patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.",DRUG0160,duvelisib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN PI3-kinase gamma (PIK3CG) PK3CG_HUMAN,CID: 50905713,Approved,Follicular lymphoma
NCT04349371,12993361,Drug,chloroquine,subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). subjects with severe gi intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04349371,12993361,Drug,chloroquine,subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). subjects with severe gi intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04349371,12993361,Drug,chloroquine,subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). subjects with severe gi intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04680949,13002575,Drug,anakinra,standard-of-care and anakinra. anakinra is injected subcutaneously as 100 mg once daily for 10 days,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04431453,13003419,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04431453,13003419,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04431453,13003419,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04391309,13003508,Drug,remdesivir,"remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on day 1, followed by 100 mg/day on days 2-5.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04391309,13003508,Drug,remdesivir,"remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on day 1, followed by 100 mg/day on days 2-5.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04391309,13003508,Drug,remdesivir,"remdesivir administered intravenously for 5 days beginning with a 200 mg loading dose on day 1, followed by 100 mg/day on days 2-5.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04363827,13003601,Drug,hydroxychloroquine,hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04362813,13003602,Drug,clazakizumab,"canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 ml of 5% dextrose infused iv over 2 hours. single dose on day 1.",DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04357808,13003618,Drug,sarilumab,single dose treatment with sarilumab 2 x 200 mg subcutaneously,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT04336332,13003662,Combination Product,hydroxychloroquine + azithromycin,given po,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04336332,13003663,Drug,hydroxychloroquine,given po,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04376814,12326149,Drug,favipiravir,"patients will be given a stat dose of 1600mg favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04376814,12326150,Drug,hydroxychloroquine,"200mg of hydroxychloroquine two times per day will be given to patients for seven days in test group, and patients in control group will be given a stat dose of 400mg hydroxychloroquine tablets two times per day.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04376684,12326170,Biological,otilimab,otilimab will be administered once via iv route.,DRUG0229,otilimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN,SID: 381127828,Phase 3,Rheumatoid arthritis
NCT04375202,12326445,Drug,colchicine,"tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04374942,12326481,Drug,hydroxychloroquine,"oral hydroxychloroquine, 400 mg taken once daily, for three months as pre-exposure prophylaxis to prevent covid-19 in health care workers in the emergency department.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04374552,12326525,Drug,hydroxychloroquine + azithromycin,drug - hydroxychloroquine sulfate &azithromycin,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04374461,12326547,Drug,n-acetylcysteine,patients in both arms will receive n-acetylcysteine iv 6 g/day in addition to supportive and/or covid-19 directed treatments at the discretion of the treating physician. treatment interruptions for up to 48 hours are permissible if there is a clinical indication to hold the study drug. patients can restart drug if they have been off drug for less than 48 hours.,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04374149,12326593,Drug,ruxolitinib,"tpe, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or ffp replacement if underlying coagulopathy combined with ruxolitinib 5mg po bid beginning day prior to first tpe and continuing bid for total of 14 days.",DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04374071,12326602,Drug,methylprednisolone,iv methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04374032,12326606,Drug,metenkefalin + tridecactide,enkorten® 5 mg + 1 mg lyophilisate for solution for injection,DRUG0119,metenkefalin + tridecactide,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,,,
NCT04374019,12326608,Drug,ivermectin,"ivermectin:~days 1-2: weight < 75kg: 4 tabs (12 mg total daily dose) days 1-2: weight > 75kg: 5 tabs (15 mg total daily dose)",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04373824,12326638,Drug,ivermectin,ivermectin 200 to 400 mcg per kg body weight,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04373044,12326763,Drug,baricitinib,given po,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04373044,12326764,Drug,hydroxychloroquine,given po,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04372082,12326908,Drug,hydroxychloroquine,200 mg x 3 per day during 10 days in addition to soc,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04372017,12326915,Drug,hydroxychloroquine,participants randomized to hydroxychloroquine will take 800mg on day 1 followed by 400mg on days 2-5.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04371926,12326929,Drug,hydroxychloroquine,"patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~staff will receive hcq sulfate 400mg/week for 4 weeks",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04371601,12326971,Drug,oseltamivir,oseltamivir capsules,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04371601,12326974,Procedure,mesenchymal stromal cells,mesenchymal stem cells,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04371523,12326984,Drug,hydroxychloroquine,"hydroxychloroquine sulfate 400mg po bid on day one, then 400mg po weekly, to be taken with meals for two months total.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04371406,12326995,Drug,hydroxychloroquine + azithromycin,"hydroxychloroquine sulfate (plaquenil®), 200mg x 3 /d, for 10 days and azithromycin (zithromax®), 500mg on d1 and then 250mg/d for the next 4 days, in addition to standard of care",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04371367,12327010,Biological,avdoralimab,intravenous administration of avdoralimab,DRUG0162,avdoralimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C5a receptor (C5aR)       C5AR1_HUMAN,,,
NCT04371107,12327044,Drug,azithromycin,"azithromycin treatment 500 mg on day 1 then 250 mg the following 4 days from day 2 to day 5, per os.",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04370834,12327087,Biological,tocilizumab,given iv,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04370782,12327091,Drug,hydroxychloroquine,"hydroxychloroquine 400mg twice a day (bid) on day 1, followed by 200mg bid for days 2-5",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04370782,12327092,Drug,azithromycin,"azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04370288,12327166,Drug,"mcn (methylene blue, vitamin c, n-acetyl cysteine)",a mixture of mcn will be injected to covid-19 patients.,DRUG0050,"mcn (methylene blue, vitamin c, n-acetyl cysteine)",Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04370015,12327190,Drug,hydroxychloroquine,health care workers at high risk of contracting sars-cov-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04369742,12327224,Drug,hydroxychloroquine,"hcq 400mg (2 tab) by mouth bid (day 1), 200mg (1 tab) by mouth bid (days 2-5)",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04369365,12327288,Drug,azithromycin,weekly oral use. azithromycin 500mg.,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04366323,12327710,Drug,mesenchymal stromal cells,two doses of 80 million adipose-tissue derived mesenchymal stem cells,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04368351,12327434,Drug,azithromycin,"dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04368351,12327435,Drug,hydroxychloroquine,"dose: 200 mg, 1 cp x 2 / day",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04367168,12327581,Drug,colchicine,"colchicine 1mg, 1 ½ pill in day 1 and ½ pill bid during 10 days in both mild and severe covid-19",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04366271,12327720,Biological,mesenchymal stromal cells,1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04366232,12327727,Drug,anakinra,anakinra 300 mg 1/d intravenous 5 days then dose tapering,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04366115,12327737,Drug,avm0703,single iv infusion at 10 mg/ml in normal saline over 1 hour to patients.,DRUG0060,avm0703,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04366089,12327745,Drug,azithromycin,"dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04366089,12327746,Drug,hydroxychloroquine,"dose: 200 mg, 1 cp x 2 / day",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04365985,12327761,Drug,naltrexone,"low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate covid-19 infection stages. naltrexone will continue for 1 month post hospital discharge. patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to ketamine arm. naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..",DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04365985,12327762,Drug,ketamine,"low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. if patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.",DRUG0085,ketamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 3821,Approved,Anaesthesia
NCT04365725,12327796,Drug,remdesivir,compassionate provision,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04365725,12327796,Drug,remdesivir,compassionate provision,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04365725,12327796,Drug,remdesivir,compassionate provision,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04365582,12327810,Drug,azithromycin,500 mg day 1 ; 250 mg/day for 4 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04365582,12327811,Drug,hydroxychloroquine,200 mg x 3/day for 10 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04365517,12327820,Drug,linagliptin,we propose a randomized controlled open label intervention study. patients with type 2 diabetes admitted to covid-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 ml / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 ml / min / 1.73 m2) in combination or not with insulin. patients with stage iv and v renal failure (estimated glomerular filtration rate less than or equal to 30 ml / min / 1.73 m2) will be excluded,DRUG0245,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4)    DPP4_HUMAN,CID: 10096344,Approved,Type 2 diabetes
NCT04365101,12327882,Biological,cynk-001,cynk-001 is an allogeneic off the shelf cell therapy enriched for cd56+/cd3- nk cells expanded from human placental cd34+ cells.,DRUG0065,cynk-001,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04364009,12328064,Drug,anakinra,"anakinra plus optimized standard of care (osoc) on the condition of patients with covid-19 infection and worsening respiratory symptoms.~the patients will receive intraveinous injection of anakinra 400mg from day 1 to day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. the total duration of anakinra is 10 days. efficient dosage of anakinra as previously described will be continued until day 10",DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04363866,12328084,Drug,hydroxychloroquine,"hydroxychloroquine is more polar, less lipophilic, and has more difficulty diffusing across cell membranes than the parent compound, chloroquine. these characteristics result in hydroxychloroquine having a longer half-life, comparatively lower toxicity to chloroquine, as well as fewer concerns pertaining to drug-drug interactions",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04363853,12328086,Drug,tocilizumab,we study the impact of the administration of tocilizumab on the evolution of the acute respiratory distress syndrome (ards) in patients with severe or critical sars-cov-2 infection.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04363736,12328104,Drug,tocilizumab,participants will receive iv tcz.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04363450,12328134,Drug,hydroxychloroquine,hydroxychloroquine loading 400mg (2 capsules) twice 12 hours apart followed by 200mg (1 capsule) twice weekly,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04363437,12328136,Drug,colchicine,"people in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. after that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04363203,12328169,Drug,hydroxychloroquine,"hydroxychloroquine: 2x200mg mg .po in the am and 2x200mg po in the pm on day 1, followed by 200mg po in the am and 200 mg po in the pm on days 2-5.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04363203,12328170,Drug,azithromycin,"azithromycin: 2x250mg by mouth (po) in the am on day 1, followed by 250mg po every day on days 2-5.",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04362332,12328269,Drug,hydroxychloroquine,cluster randomized,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04362137,12328294,Drug,ruxolitinib,ruxolitinib 5 mg tablets,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04362111,12328301,Drug,anakinra,the active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04361942,12328324,Biological,mesenchymal stromal cells,intravenous injection of 1 million msv cells/kg diluted in 100 ml saline,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04361552,12328371,Biological,tocilizumab,given iv,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04361461,12328380,Drug,hydroxychloroquine,"400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04361461,12328381,Drug,hydroxychloroquine + azithromycin,"400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04361214,12328417,Drug,leflunomide,tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.,DRUG0188,leflunomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN,CID: 3899,Approved,Multiple sclerosis
NCT04361032,12328450,Drug,tocilizumab,tocilizumab (loc) (8mg/ kg per day) (1 injection per infusion). only on the 1st day (d0),DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04361032,12328451,Drug,deferoxamine,"deferoxamine (desferal 500 mg, powder, and solvent for iv solution for injection)",DRUG0057,deferoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 2973,Approved,Acute iron or aluminum toxicity
NCT04360980,12328457,Drug,colchicine,1.5 mg loading then 0.5 mg bid p.o,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04360759,12328488,Drug,hydroxychloroquine,"chloroquine has in vitro antiviral activity against many viruses, including sars-cov-1 and sars-cov-2. chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. chloroquine inhibits viral replication through interference with glycosylation of coronavirus ace2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-ph-dependent steps of viral fusion and uncoating. chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in covid-19, where a cytokine storm has been described in critically ill patients. hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against sars-cov-2 in vitro.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04359953,12328593,Drug,hydroxychloroquine,hydroxychloroquine 2 x per day during 14 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04359953,12328594,Drug,azithromycin,azithromycin 2 x per day during 14 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04359953,12328595,Drug,telmisartan,telmisartan 2 x per day during 14 days,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 65999,Approved,Hypertension
NCT04359901,12328597,Biological,sarilumab,single dose of 400 mg subcutaneous sarilumab,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT04359667,12328631,Drug,tocilizumab,"1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04359615,12328635,Drug,favipiravir,"this will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of favipiravir in covid-19 patients.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04359615,12328636,Drug,hydroxychloroquine,this drug will be used in all arms as mandated by our governmental guidelines.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04359537,12328642,Drug,hydroxychloroquine,hydroxychloroquine sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04359316,12328678,Drug,hydroxychloroquine,this drug will be used in all arms as mandated by our governmental guidelines.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04359316,12328679,Drug,azithromycin,"this will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of azithromycin in covid-19 patients.",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04358068,12328877,Drug,hydroxychloroquine,administered orally,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04358068,12328878,Drug,azithromycin,administered orally,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04356937,12329042,Drug,tocilizumab,"patients will receive the standard treatment for covid-19 per mgh guidance and also be randomized (2:1) to one of the following arms:~tocilizumab 8mg x 1 (n=185)~standard of care/placebo (n=93)",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04681053,12289038,Drug,ivermectin,- powder administered through inhalation (6mg) bid for 3 days,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04678739,12289310,Drug,remdesivir,remdesivir 100 iv infusion as a lyophilized powder,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04678739,12289310,Drug,remdesivir,remdesivir 100 iv infusion as a lyophilized powder,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04678739,12289310,Drug,remdesivir,remdesivir 100 iv infusion as a lyophilized powder,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04678739,12289311,Drug,tocilizumab,actemra iv infusion,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04673162,12290003,Drug,methylprednisolone,iv administration,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04672564,12290068,Drug,carrimycin,"carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.",DRUG0071,carrimycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04669990,12290368,Drug,remdesivir,the objective of this registry study is to continue to collect safety and outcome data for covid-19 patients who are treated with remdesivir and convalescent plasma therapy (cpt).,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04669990,12290368,Drug,remdesivir,the objective of this registry study is to continue to collect safety and outcome data for covid-19 patients who are treated with remdesivir and convalescent plasma therapy (cpt).,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04669990,12290368,Drug,remdesivir,the objective of this registry study is to continue to collect safety and outcome data for covid-19 patients who are treated with remdesivir and convalescent plasma therapy (cpt).,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04668469,12290555,Drug,ivermectin,evaluation of the anti-parasitic medication efficacy ivermectin (ivermectin 400 mcg/kg body weight maximum 4 tablets (6mg / tablet) once daily dose before breakfast) plus standard care in the treatment of mild/moderate cases with covid 19 infection,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04668469,12290556,Drug,hydroxychloroquine,evaluation of hydroxychlorquine (400 every 12 hours for one day followed by 200 mg every 12 hours for 5 days) plus standard care in the treatment of mild/moderate cases with covid 19 infection,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04668209,12290604,Drug,silmitasertib,"standard of care / best supportive care in combination with cx-4945 1000 mg administered orally, two times a day.",DRUG0257,silmitasertib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN casein kinase II (CSK2)   CSK21_HUMAN; CSK22_HUMAN; CSK23_HUMAN; CSK2B_HUMAN,CID: 24748573,Phase 1/2,Cholangiocarcinoma
NCT04667780,12290659,Drug,colchicine,colchicine tablet 0.5 mg,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04661527,12291447,Drug,sarilumab,"treatment with sarilumab 200 mg iv x 2 doses 24 hours apart for first 5 patients. if no severe ae and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg iv for the first dose and 200 mg or 400 mg iv for the second dose 24 hours later. te second dose will be decided at the investigators discretion.",DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT04659772,12291667,Drug,clazakizumab,the patients will be given a single intravenous dose of clazakizumab 25mg. patients who fail to achieve the expected decrease in inflammatory markers following the first dose within 48 hours will have the day 1 dose repeated (clazakizumab 25 mg) on or before day 3. clazakizumab will be administered by intravenous infusion over 30 minutes.,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04652648,12292497,Drug,hydroxychloroquine,randomization was 2:1 to hcq 200 mg bid or 41 observation for 10 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04652115,12292568,Drug,defibrotide,deibrotide via iv,DRUG0076,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135565962,Approved,Hepatic Veno-Occlusive Disease
NCT04647695,12293078,Drug,interferon beta-1a,a 5-day course of subcutaneous injection of interferon β-1b 2ml (16 million iu) consecutively and iv remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04647695,12293079,Drug,remdesivir,a 5-day course of iv remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04647695,12293079,Drug,remdesivir,a 5-day course of iv remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04647695,12293079,Drug,remdesivir,a 5-day course of iv remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04647669,12293081,Drug,remdesivir,"200 mg intravenous loading dose on day 1, and 100mg intravenous once-daily for subsequent doses from day 2 up to day 10.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04647669,12293081,Drug,remdesivir,"200 mg intravenous loading dose on day 1, and 100mg intravenous once-daily for subsequent doses from day 2 up to day 10.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04647669,12293081,Drug,remdesivir,"200 mg intravenous loading dose on day 1, and 100mg intravenous once-daily for subsequent doses from day 2 up to day 10.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04647669,12293082,Drug,acalabrutinib,100 mg capsules twice daily every 12 h for 10 days taken with or without food.,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN,CID: 71226662,Approved,Leukemia
NCT04647669,12293083,Drug,interferon beta-1a,"interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug day 1, day 3, and day 6",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04646109,12293264,Drug,ivermectin,"ivermectin 5mg/5ml solution was manufactured by neutec™ pharmaceutical company-turkey, under good manufacturing practices (gmp) certification conditions.",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04636671,12294402,Drug,methylprednisolone,per-protocol methylprednisolone administration and tapering (see arm description),DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04635943,12294501,Drug,ivermectin,one daily dose of noxal-ivermectin oral solution (6 mg/ml) at 300mcg/kg for three (3) consecutive days. a weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04632706,12294895,Drug,ivermectin,"investigation of the safety, tolerability and the pharmacokinetic profile of the active imp in an exploratory study",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04627467,12295535,Drug,chloroquine,250mg tablet (150mg base chloroquine),DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04627467,12295535,Drug,chloroquine,250mg tablet (150mg base chloroquine),DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04627467,12295535,Drug,chloroquine,250mg tablet (150mg base chloroquine),DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04622891,12296115,Drug,azithromycin,azithromycin group,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04619680,12296517,Drug,nintedanib,"150 mg po twice a day, taken with food",DRUG0077,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135423438,Approved,Idiopathic pulmonary fibrosis
NCT04613271,12297275,Drug,favipiravir,"assignment of administration group 1:~favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + azithromycin 500 mg once a day for 5 days.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04613271,12297276,Drug,azithromycin,azithromycin 500 mg once a day for 5 days.,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04610541,12297580,Drug,remdesivir,remdesivir-hu 100 mg concentrate for solution for infusion,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04610541,12297580,Drug,remdesivir,remdesivir-hu 100 mg concentrate for solution for infusion,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04610541,12297580,Drug,remdesivir,remdesivir-hu 100 mg concentrate for solution for infusion,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04608214,12297886,Drug,alisporivir,administration of alisporivir at the dose of 600 mg p.o. bid from d1 to d14 to patients and standard of care (soc).,DRUG0264,alisporivir,Protein/peptide drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN cyclophilin A (CYPA)      PPIA_HUMAN,CID: 11513676,Phase 3,Hepatitis C virus infection
NCT04608214,12297886,Drug,alisporivir,administration of alisporivir at the dose of 600 mg p.o. bid from d1 to d14 to patients and standard of care (soc).,DRUG0264,alisporivir,Protein/peptide drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN cyclophilin A (CYPA)      PPIA_HUMAN,CID: 11513676,Phase 3,Hepatitis C virus infection
NCT04606563,12298097,Drug,losartan,"oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.",DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04605588,12298236,Drug,nitazoxanide,nitazoxanide (500 mg po bid for day 1and then 500 mg bid for 4 days),DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04605588,12298238,Drug,ribavirin,ribavirin (600 mg po bid for day 1and then 400 mg bid for 4 days),DRUG0152,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04605588,12298238,Drug,ribavirin,ribavirin (600 mg po bid for day 1and then 400 mg bid for 4 days),DRUG0152,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04605588,12298238,Drug,ribavirin,ribavirin (600 mg po bid for day 1and then 400 mg bid for 4 days),DRUG0152,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN,CID: 37542,,
NCT04605588,12298240,Drug,hydroxychloroquine,hydroxychloroquine sulfate (400 mg po bid for day 1 and then 200 mg bid for 4 days),DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04604678,12298346,Drug,metformin,metformin at 1500 mg/day,DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN,CID: 4091,Approved,Type 2 diabetes
NCT04604678,12298347,Drug,naltrexone,naltrexone at 4.5 mg/day (ldn),DRUG0086,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5360515,Approved,Alcoholism
NCT04603742,12298464,Drug,anakinra,100 mg of anakinra will be mixed with 100 ml of 0.9% saline solution for iv administration.,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04603729,12298467,Drug,methylprednisolone,methylprednisolone 1mg/kg/day will be given intravenous for 5 days to group 2 participants,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04603690,12298472,Drug,colchicine,1 mg tablet,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04602507,12298608,Drug,ivermectin,routinary care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04600999,12298783,Drug,favipiravir,name: avigan generic name: favipiravir content: t-705a tablets [200],DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04600895,12298793,Drug,favipiravir,favipiravir,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04597775,12299122,Drug,hydroxychloroquine,hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04596839,12299237,Drug,remdesivir,remdesivir inn 100 mg lyophilized powder for infusion,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04596839,12299237,Drug,remdesivir,remdesivir inn 100 mg lyophilized powder for infusion,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04596839,12299237,Drug,remdesivir,remdesivir inn 100 mg lyophilized powder for infusion,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04594343,12299541,Drug,disulfiram,the subject will receive 500 mg of disulfiram orally or enterally through ng tube if in mechanical ventilation once daily for 14 days,DRUG0213,disulfiram,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV papain-like proteinase (PL-PRO)        R1AB_CVHSA (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04594343,12299541,Drug,disulfiram,the subject will receive 500 mg of disulfiram orally or enterally through ng tube if in mechanical ventilation once daily for 14 days,DRUG0213,disulfiram,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV papain-like proteinase (PL-PRO)        R1AB_CVEMC (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04594343,12299541,Drug,disulfiram,the subject will receive 500 mg of disulfiram orally or enterally through ng tube if in mechanical ventilation once daily for 14 days,DRUG0213,disulfiram,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO),,Approved,Alcohol dependence
NCT04590274,12300080,Drug,hydroxychloroquine,hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04590274,12300082,Drug,azithromycin,azithromycin,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04582266,12301086,Drug,remdesivir,rdv will not be provided as part of the study. participants will be administered rdv intravenously once daily for up to 10 days per clinical care.,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04582266,12301086,Drug,remdesivir,rdv will not be provided as part of the study. participants will be administered rdv intravenously once daily for up to 10 days per clinical care.,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04582266,12301086,Drug,remdesivir,rdv will not be provided as part of the study. participants will be administered rdv intravenously once daily for up to 10 days per clinical care.,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04581954,12301116,Drug,ruxolitinib,"ruxolitinib is a janus kinase 1 (jak1)/janus kinase 2 (jak2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. it is an oral agent with a rapid mode of action.",DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04577534,12301625,Drug,tocilizumab,participants are randomized (2:1) to receive tcz or standard of care,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04575064,12301933,Drug,remdesivir,"remdesivir 200mg iv on day 1, followed by 100 mg iv daily infusion for 9 days or until discharge from hospital, whichever occurs first",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04575064,12301933,Drug,remdesivir,"remdesivir 200mg iv on day 1, followed by 100 mg iv daily infusion for 9 days or until discharge from hospital, whichever occurs first",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04575064,12301933,Drug,remdesivir,"remdesivir 200mg iv on day 1, followed by 100 mg iv daily infusion for 9 days or until discharge from hospital, whichever occurs first",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04575558,12301880,Drug,hydroxychloroquine + azithromycin,hydroxychloroquine 400mg po bid 2 times a day + azithromycin 500mg po qd,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04570449,12302481,Drug,fluvoxamine,20 mg capsule,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04570397,12302493,Drug,tocilizumab,"patients will receive weight-based dosing of ravulizumab on days 1, 5, 10, and 15 along with the standard care.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04570254,12302516,Drug,n-acetylcysteine,"n-acetylcysteine. tablets, 600 mg. 600 mg dose every 12 hours. dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.",DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04565665,12303086,Biological,mesenchymal stromal cells,given iv,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04561219,12303608,Drug,nitazoxanide,nitazoxanide 500mg three times a day for 5 days,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04561063,12303628,Drug,nitazoxanide,"nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)",DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04560231,12303731,Drug,remdesivir,"200 mg i/v remdesivir will be given to moderate disease patients of covid-19. it will be loading dose then 100 mg i/v dose will be given for 5 days. customized decision for remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of ventilation and dose will be extended up to 10 days according to clinical condition of the patients.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04560231,12303731,Drug,remdesivir,"200 mg i/v remdesivir will be given to moderate disease patients of covid-19. it will be loading dose then 100 mg i/v dose will be given for 5 days. customized decision for remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of ventilation and dose will be extended up to 10 days according to clinical condition of the patients.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04560231,12303731,Drug,remdesivir,"200 mg i/v remdesivir will be given to moderate disease patients of covid-19. it will be loading dose then 100 mg i/v dose will be given for 5 days. customized decision for remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of ventilation and dose will be extended up to 10 days according to clinical condition of the patients.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04560205,12303734,Drug,tocilizumab,"4-8mg/kg with 400mg maximum dose of tocilizumab will be given in 60 minutes i/v infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~customized decision for tocilizumab usage will be made by attending infectious diseases physician, comfort with tocilizumab usage, bacterial co-infection and duration of ventilation.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04530604,12307449,Drug,defibrotide,"all patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (iv).~the planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~patients who have not responded to study therapy by day 7 of therapy, evidenced by <20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~patients who have evidence of a partial pulmonary response by day 7 (>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course).",DRUG0076,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 135565962,Approved,Hepatic Veno-Occlusive Disease
NCT04528927,12307662,Drug,azithromycin,500 mg (1st day) then 250 mg / d for 4 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04528888,12307667,Drug,methylprednisolone,"methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04527562,12307828,Drug,colchicine,"participants in this group will be given a starting dose of 1.2 mg of colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. after that, they will take colchicine 0.6mg daily for 13 days. if they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. supportive care and treatment will also be given.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04527211,12307876,Drug,ivermectin,oral administration of ivermectin 200 mcg/kg every week for seven weeks,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04523090,12308372,Drug,nitazoxanide,"nitazoxanide (ntz) is licensed in the usa for treatment of diarrhoea caused by cryptosporidium parvum and giardia lamblia. ntz is a pro-drug for tizoxanide, which also has broad spectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against coronaviridae. ntz was identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. in vitro studies evaluating tizoxanide, the active circulating metabolite of ntz, inhibits the replication of broad range of influenza a and b, hin1, h3n2, h3n2v, h3n8, h5n9, h7n1 and oseltamivir resistant strain and coronaviruses . it has been shown to have anti-viral activity against several viruses including ebola, hepatitis b and c, rotavirus and norovirus.",DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04522986,12308380,Biological,mesenchymal stromal cells,"1*10^8 cells are administered once a week, total four times intravenously.",DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04273581,12341195,Drug,thalidomide,100mg/d，qn，for 14 days.,DRUG0068,thalidomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5426,Approved,Multiple myeloma
NCT04522466,12308441,Drug,hydroxychloroquine,"hydroxychloroquine (hcq) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/l.~measure pharmacokinetics and pharmacodynamics of hydroxychloroquine (hcq).",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04519385,12308808,Drug,tocilizumab,tocilizumab therapy,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04516941,12309110,Drug,colchicine,treatment,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04516915,12309113,Drug,imu-838,imu-838 twice daily at 22.5mg doses for 14 days,DRUG0189,imu-838,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN,CID: 9820008,,
NCT04516915,12309114,Drug,oseltamivir,oseltamivir twice daily at 75mg doses for 14 days,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04510662,12309863,Drug,telmisartan,patients in this group will receive telmisartan 40 mg daily plus standard care.,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 65999,Approved,Hypertension
NCT04510493,12309882,Drug,clazakizumab,body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04502342,12310888,Combination Product,hydroxychloroquine + azithromycin,dual treatment with hydroxycloroquine and azythromycine,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04501965,12310946,Combination Product,hydroxychloroquine + azithromycin,dual treatment with hydroxychloroquine and azythromycin,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04501783,12310966,Drug,favipiravir,tl-fvp-t will be administered orally,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04499677,12311243,Drug,favipiravir,dosage and method of administration: day 1: 1800 mg twice daily; day 2 to day 7: 400 mg four (4) times daily.,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04499313,12311285,Drug,methylprednisolone,injectable solution,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04498936,12311334,Drug,nitazoxanide,evaluate the efficacy of nitazoxanide in treatment of covid-19,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04497948,12311471,Drug,acalabrutinib,acalabrutinib (calquence®) is a covalent btk inhibitor,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN,CID: 71226662,Approved,Leukemia
NCT04497519,12311517,Drug,hydroxychloroquine,ascending dose of ihcq,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04494724,12311833,Drug,clazakizumab,infusion,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04494399,12311873,Drug,interferon beta-1a,5-day course of daily subcutaneous injection of interferon β-1b 16 million iu,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04494399,12311874,Drug,ribavirin,5-day course of oral ribavirin 400mg twice daily,DRUG0152,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04494399,12311874,Drug,ribavirin,5-day course of oral ribavirin 400mg twice daily,DRUG0152,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04494399,12311874,Drug,ribavirin,5-day course of oral ribavirin 400mg twice daily,DRUG0152,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN,CID: 37542,,
NCT04492358,12312127,Drug,colchicine,"colchicine: ideal dose of 0.3 mg/kg/day (or the dose that approximates that adjusted for age, weight and kidney function, and 0.5 mg and 1 mg tablets)",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04492501,12312110,Drug,tocilizumab,"a predefined number of patients having evidence of cytokine release storm with normal procalcitonin level for three consecutive days, a normal blood culture and il-6 level > 3 times uln will be given 1-2 doses of tocilizumab (80mg iv) . following contraindications to tocilizumab will be considered (allergy to any monoclonal ab, anc < 1000, platelets < 50, alt or ast > 5 times uln, pregnancy and breast feeding, post tb lung). some patients will receive it alone in addition to standard treatment whereas in few patients where indicated it will be given in combination with msc or remdesivir or both",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04492501,12312111,Drug,remdesivir,"it will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. for adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on day 1 followed by once daily maintenance doses of 100 mg iv for 9 days (days 2 through 10). for adults not requiring invasive mechanical ventilation 5 standard doses will be used. however, patients with known hypersensitivity to remdesivir, multi organ failure, alt > 5 times uln and gfr < 30ml/minute will not be given remdesivir. in some patients, where indicated other novel treatments including msc therapy, tocilizumab and therapeutic plasma exchange will be given.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04492501,12312111,Drug,remdesivir,"it will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. for adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on day 1 followed by once daily maintenance doses of 100 mg iv for 9 days (days 2 through 10). for adults not requiring invasive mechanical ventilation 5 standard doses will be used. however, patients with known hypersensitivity to remdesivir, multi organ failure, alt > 5 times uln and gfr < 30ml/minute will not be given remdesivir. in some patients, where indicated other novel treatments including msc therapy, tocilizumab and therapeutic plasma exchange will be given.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04492501,12312111,Drug,remdesivir,"it will be given to selected patients who have evidence of hypoxemia and presented with in 14 days of illness. for adults requiring invasive mechanical ventilation the dosage of remdesivir is a single loading dose of 200 mg sta on day 1 followed by once daily maintenance doses of 100 mg iv for 9 days (days 2 through 10). for adults not requiring invasive mechanical ventilation 5 standard doses will be used. however, patients with known hypersensitivity to remdesivir, multi organ failure, alt > 5 times uln and gfr < 30ml/minute will not be given remdesivir. in some patients, where indicated other novel treatments including msc therapy, tocilizumab and therapeutic plasma exchange will be given.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04489446,12312456,Drug,sildenafil,patients allocated to this arm will receive sildenafil 25mg every 8 hours orally for up to seven consecutive days.,DRUG0231,sildenafil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN phosphodiesterase type 5 (PDE5)   PDE5A_HUMAN,CID: 135398744,Approved,Erectile dysfunction
NCT04488081,12312624,Drug,remdesivir,"participants who receive remdesivir as part of their standard of care will be administered remdesivir by iv for up to ten days. remdesivir 200mg loading dose on day 1, followed by 100mg iv once daily maintenance doses for 4 or 9 days.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04488081,12312624,Drug,remdesivir,"participants who receive remdesivir as part of their standard of care will be administered remdesivir by iv for up to ten days. remdesivir 200mg loading dose on day 1, followed by 100mg iv once daily maintenance doses for 4 or 9 days.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04488081,12312624,Drug,remdesivir,"participants who receive remdesivir as part of their standard of care will be administered remdesivir by iv for up to ten days. remdesivir 200mg loading dose on day 1, followed by 100mg iv once daily maintenance doses for 4 or 9 days.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04487886,12312655,Drug,duvelisib,"duvelisib will be taken orally at an initial dose of 25 milligrams (mg) twice per day for 14 days. the dose will be de-escalated to 15 mg, twice per day, under certain clinical circumstances.",DRUG0160,duvelisib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN PI3-kinase gamma (PIK3CG) PK3CG_HUMAN,CID: 50905713,Approved,Follicular lymphoma
NCT04485429,12312946,Drug,methylprednisolone,"methylprednisolone 0.5 mg/kg every 12 hours intravenously for the first 14 days; followed by 0.5 mg/kg/day from day 15 to day 21; followed by 0.25mg/kg/day from day 22 to day 25; followed by 0.125 mg/kg/day, from day 26 to day 28 of treatment.",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04485429,12312947,Drug,heparin,"enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or unfractionated heparin dosed to target activated partial thromboplastin time (aptt) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). the treatment period with full-dose heparin will be 7 days. after 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.",DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04485130,12312980,Drug,disulfiram,this study will provide disulfiram. participants in cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg dsf plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. participants in cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg dsf plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.,DRUG0213,disulfiram,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV papain-like proteinase (PL-PRO)        R1AB_CVHSA (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04485130,12312980,Drug,disulfiram,this study will provide disulfiram. participants in cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg dsf plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. participants in cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg dsf plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.,DRUG0213,disulfiram,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV papain-like proteinase (PL-PRO)        R1AB_CVEMC (PL-PRO),CID: 3117,Approved,Alcohol dependence
NCT04485130,12312980,Drug,disulfiram,this study will provide disulfiram. participants in cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg dsf plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. participants in cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg dsf plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.,DRUG0213,disulfiram,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO),,Approved,Alcohol dependence
NCT04482686,12313290,Drug,ivermectin,treatment day 1 and day 4,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04479358,12313717,Drug,tocilizumab,tocilizumab 40mg,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04479358,12313718,Drug,tocilizumab,tocilizumab 120mg,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04476979,12313976,Drug,tocilizumab,tocilizumab 8mg/kg d1 and if no response (no decrease of oxygen requirement) a second fixed dose of 400mg wil be administered at d3,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04467047,12315138,Biological,mesenchymal stromal cells,intravenous 1*10e6 mscs/kg body weight mesenchymal stromal cells infusion,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04466540,12315201,Drug,hydroxychloroquine,hydroxychloroquine pharmaceutical form will be tablets of 400 mg.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04466280,12315226,Drug,hydroxychloroquine,200 mg of hydroxychloroquine daily for participants in the intervention group 1,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04466098,12315247,Biological,mesenchymal stromal cells,thawed product containing msc(300x10^6) in dmso resuspended 1:1 with dextran 40 + 5% human serum albumin [total volume 60 ml],DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04465695,12315308,Drug,interferon beta-1a,subcutaneous injection of interferon β-1b 1ml (0.5mg; 16 million iu) for 3 days,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04463264,12315591,Drug,nitazoxanide,ntx (500 mg every 6 hours for 14 days) orally with food (p.o.).,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04462757,12315642,Drug,anakinra,"100 mg interleukin-1 receptor antagonist (r-meth-hu-il-1ra), anakinra; marketed as kineret® in 0.67 ml prefilled syringe for single use",DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04461925,12315732,Procedure,mesenchymal stromal cells,i/v infusions. placenta-derived mmscs; cryopreserved placenta-derived multipotent mesenchymal stromal cells.,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04461340,12315792,Drug,sirolimus,oral dose of 6 mg on day1 followed by 2 mg daily for 9 days,DRUG0169,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN,CID: 5284616,Approved,Lymphangioleiomyomatosis
NCT04460547,12315895,Drug,hydroxychloroquine,hydroxychloroquine administration to covid-19 infected patients.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04460547,12315896,Drug,das181,das181 administration to covid-19 infected patients.,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04460547,12315897,Drug,ivermectin,ivermectin administration to covid-19 infected patients.,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04460547,12315898,Drug,interferon beta-1a,interferon beta-1a administration to covid-19 infected patients.,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04459702,12316012,Drug,hydroxychloroquine,treatment with the drug hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04459702,12316013,Drug,azithromycin,treatment with the drug azithromycin,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04459702,12316015,Drug,lopinavir,treatment with the drug lopinavir,DRUG0178,lopinavir,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,SARS-CoV 3C-like protease (3CLpro)      R1AB_CVHSA (3CLpro),CID: 92727,Approved,Human immunodeficiency virus infection
NCT04459702,12316015,Drug,lopinavir,treatment with the drug lopinavir,DRUG0178,lopinavir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,MERS-CoV 3C-like proteinase (3CLpro)    R1AB_CVEMC (3CLpro),CID: 92727,Approved,Human immunodeficiency virus infection
NCT04458948,12316103,Drug,hydroxychloroquine,"hydroxychloroquine 400 mg bid, on day 1 and then 200 mg bid day 2 through 7 iv or po for 5 days. if the condition of the patient does not allow for oral therapy, hcq can be given via a feeding or ng tube. azithromycin can be given intravenously.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04458948,12316104,Drug,azithromycin,"azithromycin 500 mg, iv or po for 5 days",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04457609,12316254,Drug,oseltamivir,current standardized treatment for covid-19,DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04457609,12316255,Drug,azithromycin,current standardized treatment for covid-19,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04457609,12316256,Biological,umbilical cord mesenchymal stem cells,adjuvant therapy on top of current standardized treatment (oseltamivir + azithromycin),DRUG0106,umbilical cord mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04455243,12316537,Drug,n-acetylcysteine,"150 mg/kg every 12 hours for 14 days (oral/iv) diluted in 200 ml diluent (d5%, ns)",DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04449380,12317272,Drug,interferon beta-1a,"ifnβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. all patients will receive a total dose of 264 mcg (72 million international units) under physician control",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04448119,12317403,Drug,favipiravir,"favipiravir is the experimental drug. the dosage for favipiravir to be used in this study for prophylaxis is 1600 mg (8 x 200 mg tablets) orally twice daily on day 1 followed by 800 mg (4 x 200 mg tablets) orally twice daily on days 2-25. the dose of favipiravir for treatment is 2000 mg orally twice daily on day 1, the 1000 mg orally twice daily for 13 additional days.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04447781,12317443,Biological,ino-4800,- manufacturer: inovio pharmaceuticals inc.,DRUG0042,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04447534,12317478,Drug,chloroquine,chloroquine,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04447534,12317478,Drug,chloroquine,chloroquine,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04447534,12317478,Drug,chloroquine,chloroquine,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04447235,12317518,Drug,ivermectin,use of the combination of ivermectin plus losartan as early treatment for covid-19 in cancer patients,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04356690,12329086,Drug,etoposide,"etoposide 150 mg/m2 administered intravenously once daily on days 1 and 4. if the treating clinicians feel that the patient initially benefited from etoposide but then has evidence of relapse of cytokine storm, the patient may continue on the standard hlh etoposide schedule of day 8, 11, 18, 25 after discussion with one of the study investigators.",DRUG0083,etoposide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 36462,Approved,Testicular neoplasms
NCT04356495,12329111,Drug,telmisartan,1 tablet daily from the first day (day 0) to day 9,DRUG0238,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 65999,Approved,Hypertension
NCT04356495,12329112,Drug,ciclesonide,2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9,DRUG0126,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6918155,Approved,Asthma
NCT04356495,12329113,Drug,interferon beta-1a,"a 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 miu / 300 µg of ifn-β-1b (extavia®) diluted in 2 ml of water",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04355793,12329232,Drug,ruxolitinib,"ruxolitinib starting dose level 5 mg orally, twice daily (bid).",DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04355676,12329243,Drug,selinexor,20 mg selinexor oral tablet.,DRUG0082,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 71481097,Approved,Multiple myeloma
NCT04355494,12329273,Biological,tocilizumab,eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses),DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04355247,12329308,Drug,methylprednisolone,"patients will be admitted to a regular room in the hospital (not icu)~they will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~methylprednisolone 80 mg iv bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04355143,12329318,Drug,colchicine,"colcrys (colchicine, usp) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine usp, administered po every 12 hours x 30 days.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04354870,12329362,Drug,hydroxychloroquine,"loading dose: 600 mg, oral, 1 day maintenance dose: 200 mg, oral, daily, for 90 days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04354805,12329368,Drug,chlorpromazine,(oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days),DRUG0199,chlorpromazine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME)       N.A.,CID: 2726,Withdrawn from market,Schizophrenia
NCT04354805,12329368,Drug,chlorpromazine,(oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days),DRUG0199,chlorpromazine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME)       N.A.,CID: 2726,Withdrawn from market,Schizophrenia
NCT04354805,12329368,Drug,chlorpromazine,(oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days),DRUG0199,chlorpromazine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN clathrin-mediated endocytosis (RME)       N.A.,CID: 2726,Withdrawn from market,Schizophrenia
NCT04354714,12329378,Drug,ruxolitinib,"for patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube",DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04354441,12329417,Drug,hydroxychloroquine,hydroxychloroquine sulfate (plaquenil) 2mg will be taken twice a day for 10 days. participants will be couriered the medication upon giving consent and will start taking the medication immediately.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04354428,12329422,Drug,hydroxychloroquine,eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04354428,12329423,Drug,azithromycin,eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04354389,12329428,Drug,das181,4.5 mg b.i.d,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04354389,12329430,Drug,das181,4.5 mg q.d.,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04354259,12329446,Drug,interferon beta-1a,"peginterferon lambda is a covalent conjugate of human recombinant non-pegylated ifn lambda (ifn l) and a 20-kda linear peg chain. peginterferon lambda injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/ml) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. lambda injection is provided in a 1-ml long type i glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. the syringe has a rigid needle shield and is stoppered with a plunger stopper. syringes are prefilled with a solution of peginterferon lambda injection, mannitol, l-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. the syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04353336,12329581,Drug,hydroxychloroquine,chloroquine or hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04353271,12329593,Drug,hydroxychloroquine,"hydroxychloroquine 800 mg initial dose then 6-8 hours later hcq 600 mg, then 200 mg three times per day for 4 days.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04352933,12329644,Drug,hydroxychloroquine,"active hcq:~days 1-2: loading phase - 400mg (2 x 200mg capsules) taken twice a day for 2 days days 3 onwards: maintenance phase - 200mg (1 x 200mg capsule) taken once a day, every day for 90 days (~3 months),~matched placebo hcq:~days 3 onwards: maintenance phase - 2 capsules taken once a week on the same day each week (every 7th day) for 90 days (~3 months)",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04352933,12329645,Drug,hydroxychloroquine,"active hcq:~days 1-2: loading phase - 400mg (2 x 200mg capsules) taken twice a day for 2 days days 3 onwards: maintenance phase - 400mg (2 x 200mg capsules) taken once a week on the same day each week (every 7th day) for 90 days (~3 months)~matched placebo hcq:~days 3 onwards: maintenance phase - 1 capsule taken once a day for 90 days (~3 months)",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04352465,12329709,Drug,methotrexate,"phase a: subjects will be dosed 20 mg of mtx iv, once per week (total of 4 doses).",DRUG0059,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 126941,Approved,Choriocarcinoma
NCT04352465,12329710,Drug,methotrexate,"phase b: subjects will be dosed 30 mg of mtx iv, once per week (total of 4 doses).",DRUG0059,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 126941,Approved,Choriocarcinoma
NCT04352465,12329711,Drug,methotrexate,"phase c: subjects will be dosed 40 mg of mtx iv, once per week (total of 4 doses).",DRUG0059,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 126941,Approved,Choriocarcinoma
NCT04351919,12329804,Drug,hydroxychloroquine,400mg per day during 10 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04351919,12329805,Drug,azithromycin,500 mg per day during 5 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04351516,12329867,Drug,hydroxychloroquine,dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04351763,12329825,Drug,amiodarone,ion channel blocker,DRUG0186,amiodarone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN two pore channel subtype 2 (TPC2) TPC2_HUMAN,CID: 2157,Approved,Ventricular tachycardia
NCT04351763,12329826,Drug,verapamil,ion channel blocker,DRUG0185,verapamil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN two pore channel subtype 2 (TPC2) TPC2_HUMAN,CID: 2520,Approved,High blood pressure
NCT04351620,12329852,Drug,hydroxychloroquine,tolerability study of hcq 1200 mg administered daily in divided doses for a duration of 5-10 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04351347,12329898,Drug,ivermectin,ivermectin,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04351295,12329908,Drug,favipiravir,favipiravir,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04351191,12329927,Drug,hydroxychloroquine,hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04351191,12329928,Drug,hydroxychloroquine,hydroxychloroquine administered as a loading dose only,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04351191,12329929,Drug,chloroquine,chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04351191,12329929,Drug,chloroquine,chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04351191,12329929,Drug,chloroquine,chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04351152,12329935,Biological,lenzilumab,administered as an intravenous (iv) infusion,DRUG0230,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN,SID: 310264716,,
NCT04350684,12330016,Drug,interferon beta-1a,this drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04350684,12330018,Drug,hydroxychloroquine,this drug will be used in all arms as mandated by our governmental guidelines.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04350671,12330020,Drug,interferon beta-1a,"this will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of interferon-β 1a in covid-19 patients.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04350671,12330022,Drug,hydroxychloroquine,this drug will be used in all arms as mandated by our governmental guidelines.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04350450,12330060,Drug,hydroxychloroquine,400 mg tablet,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04350320,12330083,Drug,colchicine,standard therapy for covid-19 according to the stablished hospital protocols.,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04350281,12330090,Drug,interferon beta-1a,daily subcutaneous injection of interferon β-1b 1ml (0.25mg; 8 million iu) consecutively on day 1 to day 3,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04350281,12330091,Drug,hydroxychloroquine,"hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04349592,12330192,Drug,hydroxychloroquine,"hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04349592,12330193,Drug,azithromycin,"azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04480138,12330336,Drug,pegylated interferon lambda,1 mcg/kg on day 1 and day 8 after safety evaluations.,DRUG0090,pegylated interferon lambda,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04349410,12330224,Drug,hydroxychloroquine + azithromycin,"fmtvdm planar, spect, pet",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04349410,12330226,Drug,hydroxychloroquine + azithromycin,"fmtvdm planar, spect, pet",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04349410,12330229,Drug,remdesivir,"fmtvdm planar, spect, pet",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04349410,12330229,Drug,remdesivir,"fmtvdm planar, spect, pet",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04349410,12330229,Drug,remdesivir,"fmtvdm planar, spect, pet",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04349410,12330230,Drug,tocilizumab,"fmtvdm planar, spect, pet",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04349410,12330231,Drug,methylprednisolone,"fmtvdm planar, spect, pet",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04349410,12330233,Drug,losartan,"fmtvdm planar, spect, pet",DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04349241,12330254,Drug,favipiravir,"pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of rna-dependent rna polymerase (rdrp) inhibitor",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04349228,12330256,Drug,hydroxychloroquine,hydroxychloroquine (hcq) 200mg/day,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04349098,12330272,Drug,selinexor,participants will receive 20 mg of selinexor.,DRUG0082,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 71481097,Approved,Multiple myeloma
NCT04348500,12330348,Drug,clazakizumab,infusion,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04348474,12330350,Drug,hydroxychloroquine,all patients included in the study will receive hcq (400 mg bid on d1 and 400 mg/day on d2 to d7) for 7 days.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04348474,12330351,Drug,azithromycin,all patients included in the study will receive azt 500 mg per day for 5 days.,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04348461,12330352,Drug,mesenchymal stromal cells,two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04348409,12330359,Drug,nitazoxanide,patients will receive nitazoxanide 600 mg bid for 7 days,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04347980,12330416,Drug,hydroxychloroquine,"patients included in the hydroxychloroquine group will benefit from standardized ventilatory management. patients included in the hydroxychloroquine group will receive 200 mg x 3 / day enterally from j1 of the hcq for 10 days. if the patient is extubated before the 10th day, he will receive his last dose of hcq before.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04347915,12330426,Drug,clevudine,clevudine 120mg once a day for 14 days (up to 21 days),DRUG0080,clevudine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 73115,Phase 4,Hepatitis B
NCT04347889,12330429,Drug,hydroxychloroquine,oral loading dose followed by once weekly dosing,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04347512,12330471,Drug,hydroxychloroquine,"patient allocated in this arm receive hydroxychloroquine for 5 days. for hydroxychloroquine, there is a loading dose of 800 mg per day at d1, followed by 400 mg per day d2-d5.~every patient receives as well antibiotic (ceftriaxone 1-2 g per day iv), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04347226,12330512,Drug,bms-986253,bms-986253 2400mg iv at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).,DRUG0159,bms-986253,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 8 (IL8)       IL8_HUMAN,SID: 385157372,,
NCT04347031,12330536,Drug,mefloquine,"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.",DRUG0013,mefloquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,,CID: 40692,Approved,Malaria
NCT04347031,12330536,Drug,mefloquine,"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.",DRUG0013,mefloquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,,CID: 40692,Approved,Malaria
NCT04347031,12330536,Drug,mefloquine,"1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.~day 2: 500 mg of mefloquine, inside, in tablets of 250 mg 2 times a day - 1 tablet every 12 hours.~3rd - 7th day: 250 mg of mefloquine, inside, in tablets of 250 mg 1 time a day at the same time.",DRUG0013,mefloquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 40692,Approved,Malaria
NCT04347031,12330537,Drug,hydroxychloroquine,"st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day;~nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04346797,12330580,Drug,tocilizumab,"intravenous administration as follows:~induction dosage regimen at 1200 mg on days 1, 4, 8 then 1200 mg or 900 mg on day 12 depending on the monitoring of eculizumab plasma level and ch5o and sc5b9 and maintenance doses of 900 mg on days 15, 18 and 22",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04346667,12330606,Drug,hydroxychloroquine,hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04346667,12330607,Drug,hydroxychloroquine,hydroxychloroquine administered as a loading dose only,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04346667,12330608,Drug,chloroquine,chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04346667,12330608,Drug,chloroquine,chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04346667,12330608,Drug,chloroquine,chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against sars-cov-2,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04346628,12330613,Drug,favipiravir,"favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04346355,12330655,Drug,tocilizumab,"in case of aggravation of covid-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg iv up to a maximum of 800 mg with repetition of the same dosage after 12 hours",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04346329,12330658,Drug,hydroxychloroquine,treated group,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04345861,12330719,Drug,hydroxychloroquine + azithromycin,combination hydroxychloroquine : 800mg(day1) then 600 mg (day 2 to day 11) azithromycin 500mg (day 1) then 250 mg (day 2 to day 5),DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04345692,12330755,Drug,hydroxychloroquine,oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04345653,12330759,Drug,hydroxychloroquine,"open-label, consecutive at-risk subjects allocation with chemoprophylaxis with hcq.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04345445,12330786,Drug,tocilizumab,iv infusion,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04345445,12330787,Drug,methylprednisolone,iv infusion,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04345419,12330790,Drug,hydroxychloroquine,chloroquine or hydroxychloroquine pills,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04345419,12330791,Drug,remdesivir,remdesivir as antiviral drug,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04345419,12330791,Drug,remdesivir,remdesivir as antiviral drug,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04345419,12330791,Drug,remdesivir,remdesivir as antiviral drug,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04344782,12330879,Drug,tocilizumab,"treatment includes the administration on day 1 (d1) of an infusion of bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. in control arm, patient receives standard care.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04343729,12331038,Drug,methylprednisolone,injectable solution at a dose of 0.5mg/kg,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04344548,12330908,Biological,allogeneic nk transfer,three doses of allogeneic nk cell transfer,DRUG0063,allogeneic nk transfer,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04344457,12330925,Drug,hydroxychloroquine,200 mg po bid 7 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04344457,12330926,Drug,indomethacin,50 mg po tid 14 days,DRUG0058,indomethacin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 3715,Approved,Rheumatoid arthritis
NCT04344444,12330930,Drug,hydroxychloroquine,tablets provided as described in arm b,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04344444,12330931,Drug,azithromycin,tablets provided as described in arm c,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04344379,12330940,Drug,hydroxychloroquine,200 mg bid per day,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04344379,12330941,Drug,azithromycin,250 mg per day,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04343976,12330994,Drug,pegylated interferon lambda,180 mcg subcutaneous injection of pegylated interferon lambda,DRUG0090,pegylated interferon lambda,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04343768,12331030,Drug,hydroxychloroquine,this drug will be used in all arms.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04343768,12331032,Drug,interferon beta-1a,this drug will be only used in arm 1.,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04343768,12331033,Drug,interferon beta-1a,this drug will be only used in arm 2.,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04343001,12331125,Drug,losartan,losartan 100mg,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04342897,12331142,Drug,ly3127804,administered iv,DRUG0161,ly3127804,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiopoietin-2 (ANG-2)    ANGP2_HUMAN,,,
NCT04342663,12331166,Drug,fluvoxamine,randomized to either fluvoxamine or placebo for approximately 15 days. will take up to 300mg per day (3 capsules per day) as tolerated.,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04342221,12331221,Drug,hydroxychloroquine,"hydroxychloroquine sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of covid-19 since it is able to block virus infection by increasing the endosomal ph, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (mapk), involved in the replication of hcov-229e and can interfere with the terminal glycosylation of ace2, thus inhibiting sars-cov-2 infection.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04342169,12331225,Drug,hydroxychloroquine,"hcq 400mg po bid x 1 day, then 200mg po bid x 4 days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04342156,12331227,Drug,hydroxychloroquine,oral tablet of 200mg hydroxychloroquine sulfate,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04341935,12331253,Drug,linagliptin,5 mg linagliptin administered by mouth once daily,DRUG0245,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4)    DPP4_HUMAN,CID: 10096344,Approved,Type 2 diabetes
NCT04341870,12331261,Drug,sarilumab,sarilumab: 400 mg in a 1 hour - i.v. infusion on d1,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT04341870,12331262,Drug,azithromycin,"azithromycin: oral administration, 500mg on d1 then 250mg qd on d2 to d5 (total duration 5 days)",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04341870,12331263,Drug,hydroxychloroquine,"hydroxychloroquine: oral administration, 600mg qd (200mg tid) from d1 to d10 (total duration 10 days)",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04372186,12331401,Drug,tocilizumab,"participants will receive one iv infusion of tcz 8 mg/kg, with a maximum dose of 800 mg. up to one additional dose may be given.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04341727,12331287,Drug,hydroxychloroquine,anti-rheumatic drug (dmard),DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04341727,12331288,Drug,azithromycin,antibiotic,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04341675,12331295,Drug,sirolimus,"sirolimus 6mg daily on day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.",DRUG0169,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN,CID: 5284616,Approved,Lymphangioleiomyomatosis
NCT04341493,12331323,Drug,nitazoxanide,clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using this option with two drugs,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04341493,12331324,Drug,hydroxychloroquine,clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (sars-cov-2) using this option with one drug,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04341441,12331334,Drug,hydroxychloroquine,"the daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. this dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~all treatment groups will receive placebo pills to have the patients take 2 pills a day.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04341441,12331335,Drug,hydroxychloroquine,"the once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. this is based on the recommended dose for prophylaxis of malaria~all treatment groups will receive placebo pills to have the patients take 2 pills a day.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04341207,12331368,Drug,hydroxychloroquine,hydroxychloroquine 200 mg 3 times a day for 10 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04341207,12331369,Drug,azithromycin,azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04341116,12331390,Drug,tj003234,patients receive a single infusion,DRUG0228,tj003234,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN,,,
NCT04341038,12331399,Drug,methylprednisolone,120mg of methylprednisolone daily for 3 consecutive days,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04340557,12331465,Drug,losartan,standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of sbp) of losartan taken twice daily for up to 10 days.,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04340544,12331466,Drug,hydroxychloroquine,"hydroxychloroquine sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of covid-19 since it is able to block virus infection by increasing the endosomal ph, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (mapk), involved in the replication of hcov-229e and can interfere with the terminal glycosylation of ace2, thus inhibiting sars-cov-2 infection.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04340349,12331498,Drug,hydroxychloroquine,a daily low dose of hydroxychloroquine sulfate. increase the endosomal ph and inhibits of ace2 glycosylation receptor.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04338958,12331693,Drug,ruxolitinib,2 x 10mg ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04339816,12331574,Drug,azithromycin,orally or into nasogastric tube for 5 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04339816,12331575,Drug,hydroxychloroquine,orally or into nasogastric tube for 5 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04339712,12331601,Drug,anakinra,in case of diagnosis of mas treatment with anakinra,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04339712,12331602,Drug,tocilizumab,in case of diagnosis of immune dysregulation treatment with tocilizumab,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04338906,12331705,Drug,hydroxychloroquine,"400 mg bid on day 1, 200 mg bid d2-d7",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04338698,12331740,Drug,hydroxychloroquine,hydroxychloroquine phosphate/sulfate (200 mg orally thrice a day for 5 days),DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04338698,12331741,Drug,oseltamivir,oseltamivir (75 mg orally twice a day for 5 days),DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04338698,12331742,Drug,azithromycin,"azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04333472,12331772,Drug,piclidenoson,piclidenoson 2 mg orally every 12 hours for up to 28 days,DRUG0075,piclidenoson,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 123683,Phase 3,Keratoconjunctivitis Sicca
NCT04337359,12331936,Drug,ruxolitinib,5 mg. tablet,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04336904,12331982,Drug,favipiravir,"dosage and method of administration: day 1: 1800mg, bid; day 2 and thereafter: 600mg, tid, for a maximum of 14 days.~where the subject has experienced an adverse event related to liver injury of grade≥3 (nci ctcae v5.0), the dose is to be reduced to 600mg bid. it is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. the subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04336748,12332002,Drug,hydroxychloroquine,low dose (200mg) hydroxychloroquine once daily for 4 weeks,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04336410,12332056,Drug,ino-4800,"ino-4800 will be administered id on day 0, week 4 and at the optional booster dose visit.",DRUG0042,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04336254,12332078,Biological,allogeneic human dental pulp stem cells (bsh btc & utooth btc),"intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of covid-19",DRUG0062,allogeneic human dental pulp stem cells (bsh btc & utooth btc),Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04335552,12332172,Drug,hydroxychloroquine,"hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04335552,12332173,Drug,azithromycin,"azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04335305,12332204,Drug,tocilizumab,iv infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04335123,12332227,Drug,losartan,25 mg qd from day 0 to day 3. dose escalation to 50 mg qd until study completion,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04335071,12332234,Drug,tocilizumab,"patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) actemra® (active ingredient: tcz) intravenously in 100 ml nacl 0.9% after confirmation of progressive dyspnoea. infusion time: 60 min. the procedure is repeated once if no clinical improvement in the 8-point who scale is observed.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04334980,12332253,Biological,bactrl-spike,"each oral dose of bactrl-spike contains bacterial medium with either 1 billion (group 1), 3 billion (group 2) or 10 billion (group 3) colony-forming-units of live bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic dna encoding spike protein from sars-cov-2.",DRUG0041,bactrl-spike,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04334967,12332254,Drug,hydroxychloroquine,"treatment arm medication will be administered on an outpatient basis. due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04334928,12332264,Drug,hydroxychloroquine,"hydroxychloroquine, 200 mg tablets. a dose of one tablet once a day will be administered.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04334512,12332329,Drug,hydroxychloroquine,treatment with hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04334512,12332330,Drug,azithromycin,treatment with azithromycin,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04334460,12332341,Drug,bld-2660,"bld-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (capn) 1, 2, and 9.",DRUG0156,bld-2660,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN calpain-2/calpain small subunit 1 dimer (CAPN2/CAPNS1)    CAN2_HUMAN/CPNS1_HUMAN,,,
NCT04334382,12332351,Drug,hydroxychloroquine,"patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po bid x 1 day, then 200mg po bid x 4 days (dose reductions for weight < 45kg). the drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the ec50 (effective concentration to suppress 50% of viral activity) of >20.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04334382,12332352,Drug,azithromycin,patients in the azithromycin arm will receive azithromycin 500mg po on day 1 plus 250mg po daily on days 2-5.,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04333914,12332439,Drug,avdoralimab,"cohorte 2 (arm h): 500mg, intravenously, at day 1 then 200mg once daily every 2 days during 14 days",DRUG0162,avdoralimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C5a receptor (C5aR)       C5AR1_HUMAN,,,
NCT04333914,12332440,Drug,tocilizumab,"cohorte 2 (arm g) : 50mg (flat dose),intravenously, single infusion at day 1.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04333654,12332467,Drug,hydroxychloroquine,pharmaceutical form:tablet route of administration: oral,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04333628,12332469,Drug,chloroquine,oral treatment of chloroquine,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04333628,12332469,Drug,chloroquine,oral treatment of chloroquine,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04333628,12332469,Drug,chloroquine,oral treatment of chloroquine,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04333589,12332475,Drug,favipiravir,"on the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. oral administration, the maximum number of days taken is not more than 14 days.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04333550,12332488,Drug,deferoxamine,intravenous infusion of deferoxamine,DRUG0057,deferoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,CID: 2973,Approved,Acute iron or aluminum toxicity
NCT04333225,12332536,Drug,hydroxychloroquine,weekly treatment in individuals at high risk,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04332991,12332570,Drug,hydroxychloroquine,"hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~for this covid-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04332107,12332695,Drug,azithromycin,participants will be shipped a single 1.2 g dose of oral azithromycin,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04332094,12332697,Drug,tocilizumab,162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1),DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04332094,12332698,Drug,hydroxychloroquine,400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total),DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04332094,12332699,Drug,azithromycin,500 mg / day v.o. for 3 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04332042,12332708,Drug,tofacitinib,tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04331899,12332727,Drug,interferon beta-1a,peginterferon lambda-1a (180 ug subcutaneous injection) single dose along with standard of care,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04331808,12332732,Drug,tocilizumab,tocilizumab 8mg/kg d1 and if no response (no decrease of oxygen requirement) a second injection at d3.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04331795,12332733,Drug,tocilizumab,"group a: tocilizumab (beginning dose 200mg) single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~second dose is provisioned if:~increasing supplemental oxygen requirement or tmax higher than baseline in the 24h following initial tocilizumab administration and~crp decrease is < 25% at 24 hours following tocilizumab administration and crp > 40mg/l",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04331795,12332734,Drug,tocilizumab,"group b: low-dose tocilizumab (beginning dose 80mg) single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~second dose is provisioned if:~increasing supplemental oxygen requirement or tmax higher than baseline in the 24h following initial tocilizumab administration and~crp decrease is < 25% at 24 hours following tocilizumab administration and crp > 40mg/l",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04331665,12332761,Drug,ruxolitinib,"ruxolitinib is an inhibitor of jak1 and jak2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.",DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04331470,12332784,Drug,levamisole pill + budesonide+formoterol inhaler,levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours budesonide+formoterol has to be inhaled 1-2 puff every 12 hours,DRUG0115,levamisole pill + budesonide+formoterol inhaler,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,,,
NCT04330690,12332887,Drug,interferon beta-1a,"interferon beta-1a containing 22 or 44 micrograms syringes will be administered subcutaneously on days 1, 3, 6.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04330690,12332888,Drug,remdesivir,"remdesivir 200mg iv on day 1, followed by 100 mg iv daily infusion for 9 days plus optimized supportive care or until discharge from hospital, whichever occurs first",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04330690,12332888,Drug,remdesivir,"remdesivir 200mg iv on day 1, followed by 100 mg iv daily infusion for 9 days plus optimized supportive care or until discharge from hospital, whichever occurs first",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04330690,12332888,Drug,remdesivir,"remdesivir 200mg iv on day 1, followed by 100 mg iv daily infusion for 9 days plus optimized supportive care or until discharge from hospital, whichever occurs first",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04330638,12332897,Drug,anakinra,"anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first",DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04330638,12332898,Drug,siltuximab,siltuximab will be given via single iv infusion at a dose of 11 mg/kg,DRUG0249,siltuximab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 124490409,Approved,Idiopathic multicentric Castleman disease
NCT04330638,12332899,Drug,tocilizumab,tocilizumab will be given via single iv infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04330495,12332914,Drug,hydroxychloroquine,chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329923,12332997,Drug,hydroxychloroquine,hydroxychloroquine 600mg twice a day,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329923,12332998,Drug,hydroxychloroquine,hydroxychloroquine 600mg twice a day,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329923,12332999,Drug,hydroxychloroquine,hydroxychloroquine 600mg twice a day,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329832,12333011,Drug,hydroxychloroquine,"patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight < 45 kg or gfr (glomerular filtration rate)<50ml/min). for patients < 45kg, doses will be halved. for patients with gfr<50ml/min, the final dose of hydroxychloroquine will not be administered. if the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329832,12333012,Drug,azithromycin,"patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). if the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04329650,12333030,Drug,siltuximab,a single-dose of 11mg/kg of siltuximab will be administered by intravenous infusion.,DRUG0249,siltuximab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 124490409,Approved,Idiopathic multicentric Castleman disease
NCT04329650,12333031,Drug,methylprednisolone,"a dose of 250mg/24 hours of methylprednisolone during 3 days followed by 30mg/24 hours during 3 days will be administered by intravenous infusion.~if the patient is taken lopinavir/ritonavir, the dose will be 125 mg/ 24 hours during 3 days followed by 15mg/24 hours during 3 days.",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04329611,12333035,Drug,hydroxychloroquine,covid19,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329572,12333043,Drug,hydroxychloroquine,all patients included in the study will receive hcq (400 mg bid on d1 and 400 mg/day on d2 to d5) for 5 days.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04329572,12333044,Drug,azithromycin,all patients included in the study will receive azt 500 mg per day for 5 days.,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04328961,12333119,Drug,hydroxychloroquine,eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04328480,12333185,Drug,colchicine,"the colchicine dosage schedule will vary according to the following scenarios:~in patients not receiving lopinavir/ritonavir~loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~the next day 0.5 mg bid for 14 days or until discharge.~in patients receiving lopinavir/ritonavir~loading dose of 0.5 mg (day 1)~after 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~patients under treatment with colchicine that are starting with lopinavir/ritonavir~dose of 0.5 mg 72 hours after starting lopinavir/ritonavir.~continue with 0.5 mg every 72 hours for 14 days or until discharge.~only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04328467,12333188,Drug,hydroxychloroquine,hydroxychloroquine; 200mg tablet; oral,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04328285,12333207,Drug,hydroxychloroquine,hydroxychloroquine oral tablets,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04328272,12333211,Drug,hydroxychloroquine,hydroxychloroquine administered orally with water,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04328272,12333212,Drug,azithromycin,azithromycin administered orally with water. 500mg oral tablet,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04326790,12333420,Drug,colchicine,"low-dose colchicine treatment, 0.5 mg bid",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04326426,12333477,Drug,tradipitant,neurokinin-1 antagonist,DRUG0122,tradipitant,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 9916461,,
NCT04325893,12333550,Drug,hydroxychloroquine,"first dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and at least 4 hours after the first dose. the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04324606,12333713,Biological,chadox1 ncov-19,a single dose of 5x10^10vp of chadox1 ncov-19,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04324489,12333731,Drug,das181,"patient receives nebulized das181 (4.5 mg bid/day, a total 9 mg/day) for 10 days.",DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04324463,12333735,Drug,colchicine,oral medication,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04324463,12333736,Drug,interferon beta-1a,subcutaneous injection,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04324073,12333813,Drug,sarilumab,(an iv dose of 400 mg of sarilumab in a 1 hour-infusion at d1,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT04324021,12333818,Biological,emapalumab,i.v infusion every third day,DRUG0183,emapalumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interferon gamma (IFNG)   IFNG_HUMAN,SID: 318164814,Approved,Primary haemophagocytic lymphohistiocytosis
NCT04324021,12333819,Biological,anakinra,daily i.v infusion,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04323761,12333862,Drug,remdesivir,intravenous infusion administered over a 30 to 120 minute period,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04323761,12333862,Drug,remdesivir,intravenous infusion administered over a 30 to 120 minute period,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04323761,12333862,Drug,remdesivir,intravenous infusion administered over a 30 to 120 minute period,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04323631,12333878,Drug,hydroxychloroquine,oral,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04323592,12333882,Drug,methylprednisolone,"usual standard of care plus methylprednisolone (mp) 80 mg/kg iv bolus, followed by mp infusion of 80 mg/day in 240 ml normal saline at 10 ml/h. the infusion is continued for at least eight days and until achieving either a pao2:fio2 > 350 mmhg or a crp < 20 mg/l. treatment is then switched to oral administration of methylprednisolone 16 mg or 20 mg iv twice daily until crp returns to < 20% of normal range and/or pao2:fio2 > 400 or sathbo2 ≥ 95%. the decision to apply the protocol to covid-19 is left to the discretion of the treating team for each individual patient.",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04322682,12334022,Drug,colchicine,"patients in this arm will receive study medication colchicine 0.5 mg per os (po) twice daily for the first 3 days and then once daily for the last 27 days. if a dose is missed, it should not be replaced.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04322565,12334040,Drug,colchicine,cochicine 1mg/day,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04322123,12334111,Drug,hydroxychloroquine,hydroxychloroquine 400 mg bid,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04322123,12334112,Drug,hydroxychloroquine + azithromycin,hydroxychloroquine 400 mg bid + azithromycin 500 mg once a day,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04321616,12334202,Drug,hydroxychloroquine,hydroxychloroquine will be given orally (in the icu in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04321616,12334203,Drug,remdesivir,remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. a loading dose of 200 mg at inclusion will be given.,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04321616,12334203,Drug,remdesivir,remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. a loading dose of 200 mg at inclusion will be given.,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04321616,12334203,Drug,remdesivir,remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. a loading dose of 200 mg at inclusion will be given.,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04321278,12334254,Drug,hydroxychloroquine + azithromycin,"intervention group: hydroxychloroquine + azithromycin. after randomization, hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. standard treatment is according to the treatment protocol for 2019-ncov infection.",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04321278,12334255,Drug,hydroxychloroquine,"active control group: hydroxychloroquine. after randomization, hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. standard treatment is according to the treatment protocol for 2019-ncov infection.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04320615,12334329,Drug,tocilizumab,participants will receive 1 dose of iv tcz. 1 additional dose may be given if clinical symptoms worsen or show no improvement.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04320277,12334380,Drug,baricitinib,baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. baricitinib tablets 4 mg were administered in the morning.,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04318444,12334655,Drug,hydroxychloroquine,"two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04318015,12334701,Drug,hydroxychloroquine,all treatment will be administered orally.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04317092,12334826,Drug,tocilizumab,"tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). a second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the investigator.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04316377,12334931,Drug,hydroxychloroquine,400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04315896,12335018,Drug,hydroxychloroquine,hydroxychloroquine 400mg day for 10 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04315480,12335086,Drug,tocilizumab,single intravenous administration 8mg/kg,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04315298,12335109,Drug,sarilumab,single or multiple intravenous (iv) doses of sarilumab. additional doses may be administered if the patient meets protocol defined criteria.,DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT04310228,12335856,Drug,favipiravir,"on the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. oral administration, the maximum number of days taken is not more than 7 days.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04310228,12335857,Drug,tocilizumab,"the first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. for fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.intravenous infusion, the maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04308668,12336098,Drug,hydroxychloroquine,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04307693,12336252,Drug,hydroxychloroquine,hydroxychloroquine sulfate tablet,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04306705,12336390,Drug,tocilizumab,administered as an intravenous infusion.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04306393,12336426,Drug,nitric oxide,"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~weaning criteria: maintenance of a pao2/fio2 ratio >/= 300 for at least 24 hours consecutively.",DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04305106,12336611,Drug,bevacizumab,"bevacizumab 7.5mg/kg body weight + 0.9% nacl 100ml, intravenous drip",DRUG0190,bevacizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN vascular endothelial growth factor (VEGF) VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN,,Approved,Metastatic colorectal cancer
NCT04305457,12336574,Drug,nitric oxide,"nitric oxide (no) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. targeted no inhaled concentration will be maintained between 140 and 180 ppm. the gas will be delivered through a cpap circuit ensuring an end-expiratory pressure between 2 and 10 cmh2o or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.",DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04303507,12336852,Drug,hydroxychloroquine,a loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04302766,12336977,Drug,remdesivir,"remdesivir (rdv,gs-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of rna virus families including filoviridae, paramyxoviridae, pneumoviridae, and orthocoronavirinae, through the targeting of the viral rna dependent rna polymerase (rdrp).",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04302766,12336977,Drug,remdesivir,"remdesivir (rdv,gs-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of rna virus families including filoviridae, paramyxoviridae, pneumoviridae, and orthocoronavirinae, through the targeting of the viral rna dependent rna polymerase (rdrp).",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04302766,12336977,Drug,remdesivir,"remdesivir (rdv,gs-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of rna virus families including filoviridae, paramyxoviridae, pneumoviridae, and orthocoronavirinae, through the targeting of the viral rna dependent rna polymerase (rdrp).",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04299724,12337443,Biological,pathogen-specific aapc,the subjects will receive three injections of 5x10^6 each covid-19/aapc vaccine via subcutaneous injections.,DRUG0039,pathogen-specific aapc,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04298060,12337659,Drug,das181,"sd (4.5mg/day), hd (9mg/day)",DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04292899,12338431,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04292899,12338431,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04292899,12338431,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04292730,12338472,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04292730,12338472,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04292730,12338472,Drug,remdesivir,administered as an intravenous infusion,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04290871,12338770,Drug,nitric oxide,"inspired no will be delivered at 80 parts per million (ppm) in the first 48 hours of enrollment. after that, no levels will be decreased to 40 ppm until severe hypoxia resolves. weaning from no will start when patients improves the level of oxygenation to a pao2/fio2 > 300 mmhg or spo2 > 93% for more than 24 hours consecutively. physician will follow their own institutional weaning protocols. in the absence of institutional protocols, no will be reduced every 4 hours in step-wise fashion starting from 40 ppm to 20, 10, 5, 3, 2 and 1 ppm.",DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04290858,12338771,Drug,nitric oxide,"nitric oxide (no) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. targeted concentration will have a tidal oscillation between 100 and 300 ppm, in order to maintain an average inhaled concentration from 140 to 180 ppm. the gas will be delivered through a cpap circuit ensuring an end-expiratory pressure between 2 and 10 cmh2o or trough a non-rebreathing mask without positive end expiratory pressure, depending on the clinical needs of the patient.",DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04288713,12339078,Drug,tocilizumab,a distal complement inhibitor.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04286503,12339374,Drug,carrimycin,carrimycin,DRUG0071,carrimycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04280705,12340201,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04280705,12340201,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04280705,12340201,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04276688,12340755,Drug,ribavirin,400mg twice daily for 14 days,DRUG0152,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04276688,12340755,Drug,ribavirin,400mg twice daily for 14 days,DRUG0152,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 37542,Approved,Hepatitis C virus infection
NCT04276688,12340755,Drug,ribavirin,400mg twice daily for 14 days,DRUG0152,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN,CID: 37542,,
NCT04276688,12340756,Drug,interferon beta-1a,0.25mg subcutaneous injection alternate day for 3 days,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04275414,12340953,Drug,tocilizumab,"bevacizumab 500mg + normal saline (ns) 100ml, ivdrip ≥90min",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04273529,12341204,Drug,thalidomide,100mg，po，qn，for 14 days.,DRUG0068,thalidomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5426,Approved,Multiple myeloma
NCT04273321,12341223,Drug,methylprednisolone,methylprednisolone 1mg/kg/day ivgtt for 7 days.,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04268537,12341953,Drug,thymosin,"thymosin 1.6 mg sc qd, last for 5 days. standard treatment is according to the protocol of treatment of 2019-ncov infection",DRUG0089,thymosin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 44286042,,
NCT04263402,12342796,Drug,methylprednisolone,"patients in the group i will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04263402,12342797,Drug,methylprednisolone,"patients in the group ii will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04261517,12343072,Drug,hydroxychloroquine,"subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04261270,12343113,Drug,oseltamivir,"75mg ,once a day",DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04260594,12343226,Drug,arbidol,"arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days",DRUG0067,arbidol,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 131410,Phase 4,Influenza virus infection
NCT04257656,12343641,Drug,remdesivir,"rdv 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04257656,12343641,Drug,remdesivir,"rdv 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04257656,12343641,Drug,remdesivir,"rdv 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04255017,12344072,Drug,oseltamivir,"oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group i.",DRUG0121,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 65028,Approved,Influenza virus infection
NCT04252664,12344414,Drug,remdesivir,"rdv 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04252664,12344414,Drug,remdesivir,"rdv 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04252664,12344414,Drug,remdesivir,"rdv 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04244591,12345519,Drug,methylprednisolone,methylprednisolone 40 mg q12h for 5 days,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04148430,12357438,Drug,anakinra,100mg subcutaneous,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04447235,12317519,Drug,losartan,use of the combination of ivermectin plus losartan as early treatment for covid-19 in cancer patients,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04446104,12317666,Drug,hydroxychloroquine,"hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04446104,12317667,Drug,ivermectin,ivermectin tablet 12mg single dose,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04445467,12317779,Drug,favipiravir,favipiravir,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04445454,12317780,Biological,mesenchymal stromal cells,bone marrow collection and msc expansion cultures will be carried out at the laboratory of cell and gene therapy (ltcg) at the university of liège as described in impd and its sops.,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04445311,12317794,Drug,ivermectin,3 successive days ttt of ivermectin started within 48 hours of symptoms,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04444674,12317856,Biological,chadox1 ncov-19,dose of 5-7.5x10^10vp of chadox1 ncov-19,DRUG0055,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04444271,12317896,Drug,mesenchymal stromal cells,"1. frozen mscs will be resuspended in 100ml normal saline for immediate use and given intravenously. the patients should be pre-medicated to avoid allergic reactions to third party mscs. each patient in experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care",DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04443881,12317950,Drug,anakinra,anakinra (100 mg/ 6 hours) i.v infusión during 15 days,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04441424,12318250,Drug,hydroxychloroquine + azithromycin,"the control group of covid-19 patients were given the conventional therapy approved in iraq for covid-19, namely hydroxychloroquine 400mg po twice per day for 5 days and azithromycin once po 500 mg per day for 5 days.",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04441398,12318252,Drug,nitazoxanide,subjects will receive nitazonanide 600 mg tid for 7 days. treatment can be extended for another 7 days at investigators discretion.,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04438980,12318540,Drug,methylprednisolone,"-a dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04438850,12318550,Drug,ivermectin,"patients will be administered a single oral daily dose of approximately 600 μg/kg (486-679 μg/kg as rounded to a whole number of tablets), or 1200 μg/kg (1098-1286 μg/kg).",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04438837,12318552,Drug,hydroxychloroquine,hydroxychloroquine post exposure prohylaxis,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04437693,12318676,Drug,hydroxychloroquine,the treatment group that will receive hydroxychloroquine (hcq) 400mg twice a day on day 1 followed by 400 mg weekly for 7 weeks,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04435808,12318928,Drug,hydroxychloroquine,"hydroxychloroquine- oral administration: duration: up to 90 days or until meeting study termination criteria. subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~loading dose: 600 mg once for the first day maintenance dose: 200 mg, daily",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04435717,12318936,Drug,tocilizumab,tocilizumab 20 mg/ml intravenous (one dose),DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04435717,12318937,Drug,tocilizumab,tocilizumab 20 mg/ml intravenous ( two doses),DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04435314,12318984,Drug,nitazoxanide,subjects will receive nitazonanide 600 mg tid for 7 days,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04434248,12319091,Drug,favipiravir,200 mg coated tablets,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04434144,12319102,Drug,hydroxychloroquine + azithromycin,"sars-cov-2 infection was confirmed by rt pcr in every case. for group b, hydroxychloroquine 400mg first day then 200mg bid + azithromycin 500mg bid for 5 days were given. for group b, hydroxychloroquine 200mg bid for 10 days and azithromycin 500mg single daily dose for 5days was given. before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for pcr was done on 5th day. for the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. in the case of positive pcr, the test was repeated after 2days and onward.",DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04431466,12319415,Drug,ivermectin,"this clinical trial will evaluate the efficacy between different ivermectin dosing schedules (100mcg / kg po single dose; 100mcg / kg po on the first day, followed by 100mcg / kg po after 72h; 200mcg / kg po single dose; and 200mcg / kg on the first day, followed by 200mcg / kg po after) for the treatment of individuals with diagnosis sars-cov-2 infection.",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04429867,12319617,Drug,hydroxychloroquine,"hydroxychloroquine 400 mg po bid x 2 doses, then 200 mg po bid x 8 doses",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04429763,12319629,Biological,umbilical cord mesenchymal stem cells,one dosis of 1*10^6 cells/kg,DRUG0106,umbilical cord mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04425707,12320134,Drug,ivermectin,"use of ivermectin in the treatment of covid 19 patients, in comparison to and in addition to the standard care of treatment of covid 19 in egypt",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04425460,12320164,Drug,favipiravir,favipiravir combined with supportive care recommended in the current national/local guidelines. favipiravir dosage and method of administration: day 1 1800 mg x2; day 2 up to a maximum of 14 days 600 mg x 3,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04423861,12320368,Drug,nitazoxanide,patients will receive nitazoxanide 600 mg bid for 7 days.,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04423042,12320473,Biological,tocilizumab,tocilizumab binds to both soluble and membrane-bound interleukin-6 receptors and has been shown to inhibit interleukin 6-mediated signalling.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04421664,12320611,Drug,hydroxychloroquine,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04420247,12320782,Drug,chloroquine,5 days of treatment with chloroquine + standard care,DRUG0010,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04420247,12320782,Drug,chloroquine,5 days of treatment with chloroquine + standard care,DRUG0010,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,,CID: 2719,Withdrawn from market,Malaria
NCT04420247,12320782,Drug,chloroquine,5 days of treatment with chloroquine + standard care,DRUG0010,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 2719,Withdrawn from market,Malaria
NCT04420247,12320783,Drug,hydroxychloroquine,5 days of treatment with hydroxychloroquine + standard care,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04414241,12321483,Drug,hydroxychloroquine,"a loading dose of 600mg of hydroxychloroquine orally on the first day, followed by 400mg of hydroxychloroquine orally every-other-day and use of standard measures of personal protection provided from the hospital for 8 weeks.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04412772,12321633,Drug,tocilizumab,participants will receive 1 dose of iv tcz. 1 additional dose may be given if clinical symptoms worsen.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04412252,12321703,Drug,tofacitinib,10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04410562,12321928,Drug,hydroxychloroquine,"participants will receive a bottle containing 19 tablets of study medication. they will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04410354,12321953,Drug,merimepodib,400 mg (total daily dose of 1200 mg) for 10 days,DRUG0251,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN,CID: 153241,Phase 2b,Hepatitis C virus infection
NCT04410354,12321955,Drug,remdesivir,"200 mg loading dose on day 0 followed by 100 mg daily dose for 4 days. if a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04410354,12321955,Drug,remdesivir,"200 mg loading dose on day 0 followed by 100 mg daily dose for 4 days. if a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04410354,12321955,Drug,remdesivir,"200 mg loading dose on day 0 followed by 100 mg daily dose for 4 days. if a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04407507,12322287,Drug,ivermectin,"ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg qid) for 14 days",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04407000,12322348,Drug,favipiravir,test drug,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04407000,12322349,Drug,favipiravir,reference drug. favipiravir 200mg.,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04406246,12322434,Drug,nitazoxanide,health workers affected by sars-cov-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04405921,12322467,Drug,hydroxychloroquine,orally or via gastric tube,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04405921,12322468,Drug,azithromycin,orally or via gastric tube,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04403685,12322745,Drug,tocilizumab,single-dose infusion of 8 mg/kg. maximum dose of 800 mg.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04403555,12322756,Drug,ivermectin,ivermectin treatment,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04403243,12322793,Drug,colchicine,0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight < 86 kg or 0.5mg twice a day per os if weight > 85kg for seven days.,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04403100,12322815,Drug,hydroxychloroquine,tablets of 400 mg: loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04403100,12322817,Drug,hydroxychloroquine,"hydroxychloroquine oral tablet 400 mg: loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days~plus~lopinavir/ ritonavir oral tablet of 200/ 50 mg: loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04402203,12322916,Drug,favipiravir,favipiravir 200 mg (favipira) tablet will be given orally. day 1: tablet favipiravir 1600 mg twice daily days 2-days 10: tablet favipiravir 600 mg twice daily.,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04401579,12322987,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04401579,12322987,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04401579,12322987,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04401579,12322988,Drug,baricitinib,"baricitinib is a janus kinase (jak) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7hpyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)azetidin-3-yl]acetonitrile each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.",DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04400032,12323178,Biological,mesenchymal stromal cells,the mesenchymal stromal cells will be administered intravenously,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04400019,12323179,Drug,hydroxychloroquine,the dose to be used as chemoprophylaxis will be 800mg of hcq on the first day and 400mg for the following four days.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04399889,12323198,Biological,mesenchymal stromal cells,infusion of human cord tissue mesenchymal stromal cells (hct-msc),DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04399798,12323209,Drug,baricitinib,4 mg/day for 7 days,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04399746,12323215,Drug,ivermectin,"6mg once daily in day 0,1,7 and 8",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04399746,12323216,Drug,azithromycin,500mg once daily for 4 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04398004,12323417,Drug,azithromycin,treatment with 500 mg clarithromycin orally twice daily for seven days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04397510,12323459,Drug,heparin,nebulized heparin,DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04397328,12323489,Drug,hydroxychloroquine,hydroxychloroquine vs placebo (1:1 design) double blind intervention,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04395768,12323674,Drug,hydroxychloroquine,active comparator group will receive: a combination of 2 drugs and 3 dietary supplements,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04395768,12323675,Drug,azithromycin,active comparator group will receive: a combination of 2 drugs and 3 dietary supplements,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04394442,12323831,Drug,hydroxychloroquine,400mg bd first day then 200 mg bd for 5 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04394416,12323832,Drug,imatinib,therapeutic,DRUG0125,imatinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 5291,Approved,Chronic myeloid leukaemia
NCT04394416,12323832,Drug,imatinib,therapeutic,DRUG0125,imatinib,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN fusion protein Bcr-Abl (Bcr-Abl)  BCR_HUMAN-ABL1_HUMAN,CID: 5291,Approved,Chronic myeloid leukaemia
NCT04394416,12323832,Drug,imatinib,therapeutic,DRUG0125,imatinib,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN fusion protein Bcr-Abl (Bcr-Abl)  BCR_HUMAN-ABL1_HUMAN,CID: 5291,Approved,Chronic myeloid leukaemia
NCT04394182,12323857,Drug,hydroxychloroquine,200 mg/12h,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04394182,12323858,Drug,azithromycin,"500 mg/24h, 3 days",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04394182,12323862,Drug,tocilizumab,600mg single dose,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04392713,12324025,Drug,ivermectin,12 mg single dose of ivermectin will be given to intervention arm,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04392219,12324084,Drug,eidd-2801,"part 1:~subjects will be randomized to receive a single oral dose of eidd-2801 or placebo.~part 2:~two single oral doses of eidd-2801 will be administered to subjects, in an open-label manner.~part 3:~subjects will be randomized to receive twice daily dosing either eidd-2801 or placebo.",DRUG0146,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 145996610,,
NCT04392128,12324094,Drug,hydroxychloroquine,"hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. hcq also inhibits ph-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04392128,12324095,Drug,azithromycin,azithromycin is amacrolide antibiotic. 500mg oral tablet,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04391127,12324203,Drug,hydroxychloroquine,hydroxychloroquine: 400 mg po every 12 hours for one day. subsequently 200 mg every 12 hours per 4 more days.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04391127,12324204,Drug,ivermectin,ivermectin 12 mg po every 24 hours for one day (in case of weight less than 80 kg) or 18 mg po every 24 hours for one day (in case of weight over 80 kg) subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04390464,12324282,Drug,tocilizumab,"ravulizumab (ultomiris, alexion pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein c5 and prevents the complement-mediated destruction of cells. it is administered by intravenous infusion. ravulizumab has a marketing authorisation in the uk for treating paroxysmal nocturnal haemoglobinuria in adults.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04390464,12324283,Drug,baricitinib,"baricitinib is administered orally once daily. it is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.",DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04390061,12324342,Drug,tofacitinib,jak-1/3 inhibitor,DRUG0074,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 9926791,Approved,Rheumatoid arthritis
NCT04390061,12324343,Drug,hydroxychloroquine,standard therapy,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04390022,12324348,Drug,ivermectin,single dose of stromectol® tablets at 400mcg/kg,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04389359,12324411,Drug,hydroxychloroquine,hydroxychloroquine sulfate administered orally for a maximum of 6 months. doses population specific.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04389320,12324415,Drug,hydroxychloroquine,assess its role in the coarse of covid 19 virus infection,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04388709,12324486,Drug,interferon beta-1a,peginterferon lambda-1a (lambda) 180mcg subcutaneous injection once,DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04387786,12324581,Drug,dornase alfa,nebulized in-line endotracheal dornase alfa co-administered with albuterol,DRUG0093,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,Approved,Cystic fibrosis
NCT04387760,12324583,Drug,hydroxychloroquine,"400mg bid po day 1 then 200mg bid po from day 2-day 10.~in addition to hydroxychloroquine all patients will receive the standard care (according to local bahrain covid19 guidelines). any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04387760,12324584,Drug,favipiravir,"1600mg bid po day 1, 600mg bid po day 2 to 10.~in addition to favipiravir all patients will receive the standard care (according to local bahrain covid19 guidelines). any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04386239,12324808,Drug,tocilizumab,sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the simet experts group 4 and aifa recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04386070,12324830,Drug,hydroxychloroquine,hydroxychloroquine only,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04385264,12324947,Drug,hydroxychloroquine,day 0: 800mg po od (4 capsules) days 1-5: 400mg po od (2 capsules daily),DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04384458,12325072,Drug,hydroxychloroquine,"oral hydroxychloroquine 400 mg twice a day on day 1, one 400 mg tablet on day 2, 3, 4, and 5, followed by one 400 mg tablets every 05 days until day 50th associated with 66 mg of zinc sulfate.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04384458,12325073,Drug,ivermectin,"oral ivermectin dosage guidelines based on participant body weight, once on day for 2 consecutive days. this dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.",DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04384380,12325079,Drug,hydroxychloroquine,hydroxychloroquine sulfate is 400 mg bid on day 1 and 200 mg bid for 6 days on day 2-7.,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04382053,12325402,Drug,dfv890,dfv890 administerated in addition to the soc for 14 days,DRUG0094,dfv890,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04383002,12325279,Drug,nitric oxide,"ino will be given at 160ppm for 6 hours, once a day, for 2 days",DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04382846,12325297,Drug,nitazoxanide,nitazoxanide,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04382040,12325408,Drug,artemic,treatment will be sprayed orally twice a day for the first 2 days in the treatment period,DRUG0088,artemic,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 11629819,,
NCT04381988,12325415,Drug,hydroxychloroquine,400mg daily,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04381962,12325421,Drug,azithromycin,azithromycin 500 mg od po 14 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04381884,12325441,Drug,ivermectin,ivermectin (iver p®) arm will receive ivm 600 µg / kg once daily plus standard care. control arm will receive standard care.,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04381052,12325551,Drug,clazakizumab,dose is 25mg intravenously over 30 minutes.,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04729491,12325680,Drug,azithromycin,azithromycin 500mg/day for 05 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04729491,12325681,Drug,nitazoxanide,500mg twice daily for 06 days,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04380818,12325586,Drug,hydroxychloroquine,200 mg/12h for 5 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04380818,12325588,Drug,tocilizumab,600 mg/day for 1-2 doses,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04380818,12325589,Drug,azithromycin,500 mg/24h for 3 days,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04380688,12325609,Drug,acalabrutinib,acalabrutinib administered orally,DRUG0163,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN,CID: 71226662,Approved,Leukemia
NCT04380402,12325656,Drug,atorvastatin,atorvastatin 40 mg tablet,DRUG0158,atorvastatin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN MYD88-NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)     N.A.,CID: 60823,Approved,Hyperlipidemia
NCT04380376,12325660,Drug,melphalan,inhalations with low doses of melphalan for 7-10 consequent days,DRUG0087,melphalan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 460612,Approved,Ovarian neoplasms
NCT04379518,12325794,Drug,rintatolimod,given iv,DRUG0155,rintatolimod,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,HUMAN toll-like receptor 3 (TLR3)       TLR3_HUMAN,CID: 135537060,Phase 3,Chronic Fatigue Syndrome
NCT04379492,12325797,Drug,hydroxychloroquine,"participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04379271,12325830,Drug,imu-838,"tablets will be taken bid with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~if the patient is intubated for ventilation, imp is to be given via a gastric tube. the tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube.",DRUG0189,imu-838,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN,CID: 9820008,,
NCT04728880,12326101,Drug,remdesivir,this study is a retrospective trial to assess the efficacy of remdesivir in adult patients diagnosed with covid-19 in mansoura university isolation hospital. in this study we will analyze the data collected during treatment.,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04728880,12326101,Drug,remdesivir,this study is a retrospective trial to assess the efficacy of remdesivir in adult patients diagnosed with covid-19 in mansoura university isolation hospital. in this study we will analyze the data collected during treatment.,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04728880,12326101,Drug,remdesivir,this study is a retrospective trial to assess the efficacy of remdesivir in adult patients diagnosed with covid-19 in mansoura university isolation hospital. in this study we will analyze the data collected during treatment.,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04377750,12326045,Drug,tocilizumab,the placebo treatment arm will include 100 ml of normal saline administered along 60 min,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04377711,12326047,Drug,ciclesonide,160mcg inhaler,DRUG0126,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6918155,Approved,Asthma
NCT04377659,12326055,Drug,tocilizumab,"participants will receive tocilizumab 8 mg/kg i.v. at enrollment. dose will be capped at 800 mg per infusion. if there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04377646,12326056,Drug,hydroxychloroquine,"400 mg at day 1 and day 2, then 400 mg weekly up to 2 months",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04377620,12326063,Drug,ruxolitinib,ruxolitinb administered bid approximately 12 hours apart,DRUG0202,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN,CID: 25126798,Approved,Myelofibrosis
NCT04377503,12326077,Drug,tocilizumab,tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. the dose will be repeated after 12 hours.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04377503,12326078,Drug,methylprednisolone,patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. then they will receive 1 mg / kg / day for another 7 days. finally 0.5 mg / kg / day until 21 days of use,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04377308,12326095,Drug,fluvoxamine,fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04559113,12303857,Drug,methylprednisolone,"0.5mg to 1mg/kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~methylprednisolone 1 mg/kg daily iv for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day.",DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT04558463,12303932,Drug,favipiravir,"the favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin c, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04554979,12304379,Drug,hydroxychloroquine,"hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. also they received anticoagulants, vitamin c and zinc. in case of secondary bacterial infection, empiric antibiotics are started",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04552483,12304690,Drug,nitazoxanide,nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of covid-19.,DRUG0127,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 41684,Approved,Diarrhea
NCT04552379,12304704,Biological,interferon beta-1a,"administration of trial drug: plegridy is given by an injection under the skin (subcutaneous injection). it will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. rn or md). they will wait for 20 mins after the last individual receives the interferon before leaving a residence. administering staff will be supplied with appropriate ppe, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~plegridy will be administered in the home of the participants. due to the heat-labile nature of the trial product (storage required at ~4oc) a verified english spanish version of the product label will be printed by a gmp certified company and applied to the product and patient band just at the time of use.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT04552366,12304705,Biological,ad5-ncov,recombinant novel coronavirus vaccine (adenovirus type 5 vector),DRUG0066,ad5-ncov,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04545008,12305643,Drug,n-acetylcysteine,oral n-acetyl cysteine,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04542993,12305892,Dietary Supplement,resveratrol,resveratrol 2 grams po bid x 5 days,DRUG0036,resveratrol,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,,CID: 445154,,
NCT04542694,12305927,Drug,favipiravir,200 mg coated tablets,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04539873,12306304,Drug,colchicine,"patientes in this arm will receive study medication colchicine 1,5 orally on the first day (initially two pills of 0,5 mg and 0.5 mg at 2 hours), followed by 0.5 mg every 12 hours on days 2 to 7, and continuing with 0.5 mg per day until completing 14 ± 1 days. the duration of treatment will be 14 ± 1 days, depending on the clinical judgment of the investigator.",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04537351,12306616,Biological,cynk-001,"the active agent in cyp-001 is cymerus mesenchymal stem cells (mscs), which are derived through a proprietary induced pluripotent stem cell (ipsc) and mesenchymoangioblast (mca)-derived production process.",DRUG0065,cynk-001,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,,,,
NCT04534725,12306938,Drug,selinexor,oral tablet,DRUG0082,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 71481097,Approved,Multiple myeloma
NCT04534725,12306939,Drug,lenzilumab,intravenous infusion,DRUG0230,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN,SID: 310264716,,
NCT04532372,12307224,Drug,leflunomide,given po,DRUG0188,leflunomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN,CID: 3899,Approved,Multiple sclerosis
NCT02735707,12538969,Drug,anakinra,"a loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. this is followed by maintenance doses of 100mg of anakinra administered very 6 hours.~in patients with renal impairment, anakinra will be administered on alternate days.",DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT02735707,12538966,Drug,hydroxychloroquine,"loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or icu discharge (whichever occurs first).",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT02735707,12538968,Drug,interferon beta-1a,"ifn-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. ifn-β1a will be administered once daily for 6 days or until icu discharge, whichever occurs first.",DRUG0129,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,Approved,Multiple sclerosis
NCT02735707,12538972,Drug,sarilumab,"sarilumab will be administered as a single dose of 400mg, via iv infusion through peripheral or central line over a one-hour period.",DRUG0204,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Rheumatoid arthritis
NCT02735707,12538971,Drug,tocilizumab,"tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~tocilizumab will be administered as an iv infusion via central or peripheral line over a one-hour period.",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04640168,13018292,Drug,baricitinib,"baricitinib is a janus kinase (jak) inhibitor with the chemical name [1-(ethylsulfonyl)-3-(4-(7hpyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)azetidin-3-yl]acetonitrile. each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.",DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04640168,13018295,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04640168,13018295,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04640168,13018295,Drug,remdesivir,"drug remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524. in addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (sbecd), and hydrochloric acid and/or sodium hydroxide.",DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04593940,13018524,Drug,remdesivir,standard of care,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04593940,13018524,Drug,remdesivir,standard of care,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04593940,13018524,Drug,remdesivir,standard of care,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04546581,13018747,Drug,remdesivir,remdesivir will be given to participants in both groups as standard of care (soc).,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04546581,13018747,Drug,remdesivir,remdesivir will be given to participants in both groups as standard of care (soc).,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04546581,13018747,Drug,remdesivir,remdesivir will be given to participants in both groups as standard of care (soc).,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04501978,13018963,Biological,remdesivir,provided to all study participants as soc unless contraindicated for an individual patient.,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04501978,13018963,Biological,remdesivir,provided to all study participants as soc unless contraindicated for an individual patient.,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04501978,13018963,Biological,remdesivir,provided to all study participants as soc unless contraindicated for an individual patient.,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04357366,13019514,Drug,anakinra,treatment with 100mg anakinra subcutaneously (sc) once daily for ten days,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04322396,13019606,Drug,azithromycin,azithromycin,DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04322396,13019607,Drug,hydroxychloroquine,hydroxychloroquine,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04312009,13019633,Drug,losartan,losartan; 50 mg daily; oral administration,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04311177,13019637,Drug,losartan,losartan; 25 mg daily; oral administration,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04655586,13025443,Drug,heparin,standard of care heparin per institution (therapeutic or prophylactic regimen),DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04649151,13025455,Biological,mrna-1273,sterile liquid for injection,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04529525,13025891,Drug,ivermectin,patients will receive the tablet from the branch to which they were randomized only at the time of inclusion and 24 hours after the first dose.,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04470427,13026073,Biological,mrna-1273,sterile liquid for injection,DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04419025,13026239,Drug,n-acetylcysteine,oral formulation: 600 mg capsules of n-acetylcysteine,DRUG0069,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 12035,Approved,Cystic fibrosis
NCT04373733,13026367,Drug,favipiravir,anti-viral,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04363502,13026386,Drug,clazakizumab,the route of administration will be intravenous. each dose will be administered as an infusion that is run over 30 minutes.,DRUG0247,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 160671637,,
NCT04338828,13026439,Drug,nitric oxide,inhaled no administered at target inspired concentration 140 - 300 ppm for 20-30 minutes,DRUG0072,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 145068,Approved,Hypertension
NCT04331834,13026456,Drug,hydroxychloroquine,"hydroxychloroquine with the following dosage:~day 0: 400 mg (2 tablets)~day 1: 400 mg (2 tablets)~day 2: 400 mg (2 tablets)~day 3: 400 mg (2 tablets)~weekly: 400 mg (2 tablets) for a period of six months",DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04328012,13026465,Drug,losartan,administered 14 days,DRUG0239,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN,CID: 3961,Approved,Hypertension
NCT04283461,13026557,Biological,mrna-1273,"lipid nanoparticle (lnp) dispersion containing an mrna that encodes for the prefusion stabilized spike protein 2019-ncov. mrna-1273 consists of an mrna drug substance that is manufactured into lnps composed of the proprietary ionizable lipid, sm-102, and 3 commercially available lipids, cholesterol, dspc, and peg2000 dmg.",DRUG0038,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04472585,13031367,Drug,ivermectin,subcutaneous ivermectin 200ug/kg body weight 48 hourly,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04472585,13031371,Drug,ivermectin,0.2mg/kg/day,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04380961,13031564,Drug,sirukumab,participants will receive sirukumab 5 mg/kg iv single dose infusion on day 1.,DRUG0246,sirukumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN,SID: 135626800,Phase 3,Rheumatoid arthritis
NCT04703608,13035482,Drug,ivermectin,ivermectin 0.3-0.4mg/kg daily for 3 days.,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04421027,13036393,Drug,baricitinib,given orally,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04412291,13036412,Drug,anakinra,a total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.,DRUG0225,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN,CID: 139595263,Approved,Rheumatoid arthritis
NCT04412291,13036413,Drug,tocilizumab,"8mg/kg for a single infusion iv up to max 800 mg. if no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: the clinical symptoms are worsened (as assessed by decreasing pao2/fio2 and/or need of increased ventilatory support such as niv, hfnc or mechanical ventilation).",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04716569,13040909,Drug,ivermectin,usage of ivermectin as intranasal spray for treating early covid patiens,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04642638,13041074,Drug,ino-4800,ino-4800 will be administered id on day 0 and day 28.,DRUG0042,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,,,,
NCT04600141,13041200,Drug,tocilizumab,tocilizumab infusion 8mg/kg/dose - intravenous single dose.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04583969,13041239,Biological,lenzilumab,"lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human gm-csf, with potential immunomodulating activity, high binding affinity in the pm range, and 94% specificity to the human germline, which reduces immunogenicity.",DRUG0230,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN,SID: 310264716,,
NCT04583969,13041241,Drug,remdesivir,remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524.,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04583969,13041241,Drug,remdesivir,remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524.,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04583969,13041241,Drug,remdesivir,remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog gs-441524.,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04583956,13041243,Drug,remdesivir,remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog gs-441524.,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04583956,13041243,Drug,remdesivir,remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog gs-441524.,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04583956,13041243,Drug,remdesivir,remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog gs-441524.,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04539262,13041330,Drug,remdesivir,administered as an aerosolized solution,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04539262,13041330,Drug,remdesivir,administered as an aerosolized solution,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04539262,13041330,Drug,remdesivir,administered as an aerosolized solution,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04510194,13041396,Drug,metformin,"metformin; immediate release formation; 1,500mg daily",DRUG0252,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN,CID: 4091,Approved,Type 2 diabetes
NCT04510038,13041398,Drug,colchicine,"colchicine dosing = 0.6 mg bid x 30 days decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) decrease dose to 0.6 mg daily in the setting of weak or moderate cyp3a4 inhibitor decrease dose to 0.3 mg daily in the setting of strong cyp3a4, p-glycoprotein inhibitors, or protease inhibitors decrease dose to 0.3 mg daily in the setting of ckd stage ≥ 4 (crcl ≤ 30 ml/min) or liver failure (ast/alt > 3x normal).~decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (esrd) or requiring dialysis route of administration: oral",DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04464408,13041470,Drug,favipiravir,"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily",DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04405739,13041556,Drug,eidd-2801,oral capsule of eidd-2801,DRUG0146,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 145996610,,
NCT04405570,13041558,Drug,eidd-2801,oral capsule of eidd-2801,DRUG0146,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 145996610,,
NCT04334148,13041668,Drug,hydroxychloroquine,oral self administered tablet,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04727775,12283345,Drug,favipiravir,antiviral drugs,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04727775,12283346,Drug,remdesivir,antiviral drugs,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04727775,12283346,Drug,remdesivir,antiviral drugs,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04727775,12283346,Drug,remdesivir,antiviral drugs,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04724629,12283735,Drug,colchicine,0.5 mg of indirect il-6 inhibitor,DRUG0073,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 6167,Approved,Gout
NCT04723563,12283862,Drug,heparin,"25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization",DRUG0145,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,,CID: 772,Approved,Venous thrombosis
NCT04720612,12284210,Biological,tocilizumab,single subcutaneous dose of 375mg of omalizumab and standard of care.,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04718480,12284461,Drug,fluvoxamine,po fluvoxamine tablets,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT04715295,12284876,Combination Product,hydroxychloroquine + azithromycin,hydroxychloroquine 400mg daily from day 1 to day 5 in combination with azithromycin 500mg on day 1 and 250 mg daily from day 2 to day 5,DRUG0133,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,,,
NCT04714515,12284969,Drug,hydroxychloroquine,an fda approved antiarthritis drug,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04714515,12284970,Drug,ivermectin,an fda approved anti-parasitic medicine,DRUG0111,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,,CID: 6321424,Approved,Onchocerciasis
NCT04713878,12285057,Other,mesenchymal stromal cells,intravenous infusion of mesenchymal stem cells,DRUG0109,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,,,
NCT04712279,12285267,Drug,hydroxychloroquine,hydroxychloroquine 200mg/day q.d. for 05 days,DRUG0192,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.,CID: 3652,Approved,Malaria
NCT04711863,12285314,Drug,fluvoxamine,up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days,DRUG0078,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,,CID: 5324346,Approved,Obsessive-compulsive disorder
NCT03808922,13042515,Drug,das181,das181 4.5mg nebulized qd x 7 or 10 days,DRUG0128,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,SID: 381125922,,
NCT04699097,12286855,Drug,azithromycin,"250 mg tablet, 5 ml / 200 mg 30 ml suspension",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT04694612,12287407,Drug,favipiravir,comparison of clinical improvement and clinical deterioration between those receiving favipiravir compared to placebo in the patients with mild covid-19,DRUG0234,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 4424075,Approved,Influenza virus infection
NCT04694612,12287409,Drug,remdesivir,comparison of clinical improvement and clinical deterioration between those receiving favipiravir compared to remdesivir injection in the patients with moderate covid-19,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04694612,12287409,Drug,remdesivir,comparison of clinical improvement and clinical deterioration between those receiving favipiravir compared to remdesivir injection in the patients with moderate covid-19,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04694612,12287409,Drug,remdesivir,comparison of clinical improvement and clinical deterioration between those receiving favipiravir compared to remdesivir injection in the patients with moderate covid-19,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04693026,12287606,Drug,remdesivir,remdesivir 100 iv infusion as a lyophilized powder,DRUG0233,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 121304016,,
NCT04693026,12287606,Drug,remdesivir,remdesivir 100 iv infusion as a lyophilized powder,DRUG0233,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 121304016,,
NCT04693026,12287606,Drug,remdesivir,remdesivir 100 iv infusion as a lyophilized powder,DRUG0233,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 121304016,,
NCT04693026,12287607,Drug,baricitinib,baricitinib oral tablet form,DRUG0191,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN,CID: 44205240,Approved,Rheumatoid arthritis
NCT04693026,12287608,Drug,tocilizumab,tocilizumab iv infusion,DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT04690920,12287836,Drug,tocilizumab,"comparison of drugs, tocilizumab, remdesivir, standard treatment with controls",DRUG0203,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN,,Approved,Giant cell arteritis
NCT03852537,12393571,Drug,methylprednisolone,methylprednisolone will be administered based on crp-guided protocol outlined under 'biomarker-adjusted steroid dosing'.,DRUG0124,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 6741,Approved,Rheumatoid arthritis
NCT03871491,12391106,Drug,azithromycin,"the study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. by random allocation, participants will receive 2 g of oral azithromycin.",DRUG0123,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,,CID: 447043,Approved,Bronchitis
NCT03891420,12388642,Drug,galidesivir,galidesivir iv infusion,DRUG0232,galidesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp),CID: 69211190,,
NCT03891420,12388642,Drug,galidesivir,galidesivir iv infusion,DRUG0232,galidesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp),CID: 69211190,,
NCT03891420,12388642,Drug,galidesivir,galidesivir iv infusion,DRUG0232,galidesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp),CID: 69211190,,
